hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche finance report finance report finance brief finance brief key result roche roche group report good overall result sale grow constant exchange rate cer ifrs net income increase sale core operating profit margin cer growth sale core earning share pharmaceutical sale diagnostic group sale increase cer chf billion growth chf term pharmaceutical sale growth cer continued growth franchise mabtherarituxan oncology portfolio immunology sale actemraroactemra esbriet xolair increase avastin sale stable sale pegasys tarceva lucentis decrease competitive pressure group diagnostic sale show growth cer centralise point care solution business major contributor operating result change sale chf chf chf cer core operating profit increase cer chf billion increase chf term ifrs result research development expenditure grow cer chf billion core basis focus oncology immunology sale therapeutic area research development cost represent group sale operating profit ifrs operating result include noncore expense pretax chf billion major factor chf billion amortisation net income intangible asset chf billion impairment goodwill intangible asset chf billion global restructuring plan notably net income attributable roche shareholder pharmaceutical division strategic realignment manufacturing network dilute eps chf dividend share chf nonoperating result core result core net financial expense decrease chf billion chf billion drive low foreign exchange loss low interest expense research development partially offset high loss bond redemption core operate profit ifrs net financial expense decrease chf billion chf billion result decrease core net financial expense core eps chf ifrs net financial expense include loss chf billion major debt restructure free cash flow net income operate free cash flow free cash flow ifrs net income increase cer chf billion increase chf term core earning share increase cer chf term change chf chf chf cer net debt cash flow operate free cash flow remain strong chf billion underlying growth operate cash generation offset capitalisation high capital expenditure increase net work capital high investment intangible asset lead decrease cer debt chf term equity free cash flow decrease cer chf term chf billion drive low operate free cash flow high pension contribution propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant exchange rate average rate year end december definition cer financial position core result core ep earning share exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset net work capital increase cer increase receivables drive increase sale high inventory allow assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result given partly offset high payable net debt decrease chf billion generate free cash flow offset dividend pay net debt percentage group refine calculation free cash flow exclude dividend line peer group free cash flow restate accordingly result total asset increase chf million free cash flow period impact operate free cash flow change definition free cash flow credit rating strong moodys standard poor detailed breakdown page shareholder return dividend proposal increase dividend chf share represent consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr minus represent combine performance share nonvoting equity securityfinancial review roche group roche group financial review roche group result finance brief inside cover finance brief sale billion chf core operating profit billion chf financial review cer growth sale roche group consolidated financial statement note roche group consolidate financial statement general accounting principle noncurrent liability operate segment information current liability net financial expense provision contingent liability net income attributable roche shareholder billions chf core eps chf income taxis debt business combination equity attributable roche shareholder global restructuring plan subsidiarie property plant equipment noncontrolle interest goodwill employee benefit intangible asset pension postemployment benefit inventory equity compensation plan account receivable earning share nonvoting equity security marketable security statement cash flow roche group result show sale growth constant exchange rate cer ifrs operating profit cash cash equivalent risk management core operating profit core eps sale increase drive pharmaceutical division oncology portfolio noncurrent asset relate party especially franchise centralise point care solution business diagnostic division current asset subsidiary associate increase expenditure research development launch expense new product offset income change account payable significant accounting policy group swiss pension plan additionally cost grow diagnostic division expansion sequence business operate free cash flow chf billion sale decrease high capital expenditure increase net work capital increase investment intangible asset report roche management internal control financial reporting sale pharmaceutical division rise chf billion increase drive oncology portfolio especially statutory auditor report general meeting roche holding ltd basel franchise grow sale immunology grow actemraroactemra xolair increase respectively sale pegasys tarceva lucentis decline competitive pressure regional growth significant report independent auditor internal control financial report europe diagnostic sale grow consolidate division lead market position major growth area board director roche holding ltd basel centralise point care solution sale increase molecular diagnostic tissue diagnostic sale increase respectively sale diabetes care decrease continue challenge market condition multiyear overview supplementary information ifrs operating profit increase pharmaceutical division diagnostic division increase roche security core operating profit respectively pharmaceutical division cost sale increase manufacturing cost offset low royalty expense market distribution cost grow drive launch cost new product notably tecentriq ocrevus research development continue investment oncology especially cancer immunotherapy field immunology cost sale diagnostic division grow unfavourable product mix high cost external supplier research development expense increase sequence molecular diagnostic business result division roche holding ltd basel positively impact accounting effect change group swiss pension plan operate free cash flow chf billion remain strong growth cash generation business offset financial statement high capital expenditure increase net work capital high investment intangible asset capital expenditure include manufacture investment switzerland germany chugai site development activity switzerland note financial statement south san francisco campus increase net work capital come inventory increase spending launch preparation factor combine decrease cer chf term relative free appropriation available earning cash flow chf billion decrease lower operate free cash flow high pension contribution statutory auditor report general meeting roche holding ltd basel core basis net financial expense low reduction foreign exchange loss low interest expense ifrs basis additionally low comparative result include loss chf billion major debt restructure group effective tax rate high defer tax impact arise tax rate change roche finance report roche group financial review financial review roche group net income increase cer ifrs basis core basis addition item describe core result sale ifrs result reflect impact high intangible asset impairment amortisation offset release contingent consideration provision sale increase cer chf usd chf billion sale pharmaceutical division rise chf billion drive growth franchise actemraroactemra mabtherarituxan esbriet xolair compare swiss franc weak major currency particular japanese yen dollar sale grow region particularly europe franchise grow respectively overall avastin euro overall impact positive result express swiss franc compare constant exchange rate sale remain stable decrease offset high sale international region sale pegasys tarceva percentage point impact sale core operating profit percentage point core eps lucentis decline competitive pressure total chf billion recently launch product alecensa tecentriq cotellic add chf billion sale income statement sale diagnostic division chf billion increase cer consolidate lead market position major change change chf chf chf cer growth area centralise point care solution professional diagnostic represent half ifrs result division sale growth lead immunodiagnostic business sale molecular diagnostic tissue diagnostic sale increase respectively diabetes care sale decrease impact continue challenge market condition royalty operating income north america cost sale marketing distribution divisional operating result research development pharmaceutical diagnostic corporate group general administration chf chf chf chf operating profit sale core operating profit financing cost margin sale financial income expense operate profit profit taxis margin sale operate free cash flow income taxis margin sale net income attributable divisional operating result development result compare roche shareholder noncontrolle interest pharmaceutical diagnostic corporate group sale eps basic chf increase cer eps diluted chf core operating profit increase cer core result margin percentage point increase sale operating profit royalty operating income increase cer cost sale margin percentage point increase marketing distribution operate free cash flow research development increase cer general administration margin percentage point increase operating profit financing cost financial income expense core operating result profit taxis significant income item core result chf million change group pension plan income taxis switzerland chf million tax cer positive margin impact percentage point group percentage net income point pharmaceutical division percentage point diagnostic division exclude item core operating profit grow group pharmaceutical division decline diagnostic division attributable roche shareholder pharmaceutical division division core operating profit increase cer ahead sale increase manufacture noncontrolle interest cost sale grow result investment internal external biologic manufacture network royalty expense decrease expiry patent increase expenditure research development especially oncology core ep basic chf immunology launch expense tecentriq ocrevus new product partly offset income core ep diluted chf swiss pension plan change diagnostic division core operating profit increase cer increase sale cost sale higher unfavourable product mix high instrument placement high cost external supplier research development cost increase sequence business partly offset income swiss pension plan change roche finance report roche finance report roche group financial review financial review roche group acquisition impairment goodwill intangible asset roche group complete business combination chf million noncore income impairment charge chf million pharmaceutical division large item chf million relate release contingent consideration provision mainly partial reversal provision relate seragon trophos decision stop development compound acquire seragon acquisition follow clinical datum assessment acquisition intangible asset impairment charge chf million chf million related seragon trophos additionally half chf million relate delay development compound acquire respectively offset provision reversal note impairment goodwill intangible asset commentary trophos acquisition follow regulatory feedback relate release contingent consideration provision noncore cost include expense chf million chf million release esbriet inventory fair value acquisition increase income total chf million note acquisition commentary major adjustment fully unwound detail give note annual financial statement item impairment charge chf million compound follow portfolio reassessment diagnostic division record impairment charge chf million large item impairment sequence global restructuring plan product intangible use chf million result decision stop product development commercialisation licence agreement alliance partner group continue implementation major global restructuring plan initiate prior year notably strategic realignment pharmaceutical division manufacturing network programme address longterm strategy detail give note annual financial statement diagnostic division global restructuring plan cost incur millions chf pension postemployment benefit diagnostic site consolidation plan total operating income chf million record past service cost change group pension plan global restructuring cost switzerland announce june represent impact adjustment pension liability plan employeerelate cost change chf million record pharmaceutical division chf million diagnostic division site closure cost chf million corporate aftertax impact chf million pension contribution high reorganisation expense additional contribution plan switzerland ireland information group pension post total global restructuring cost employment benefit give note annual financial statement additional cost impairment goodwill legal environmental case impairment intangible asset legal environmental case legal environmental case include increase provision chf million environmental matter follow divestment nutley site significant development detail give note annual financial total cost statement include diabete care autonomy speed restructuring plan include pharmaceutical division strategic realignment manufacturing network include plan pharmaceutical division research development strategic realignment outsource treasury taxation diagnostic division cost roche diabetes care autonomy speed initiative chf million mainly finance cost low ifrs basis loss comparative period chf million major debt consultancy itrelate matter employeerelate cost new strategy plan diagnostic diabetes care incur cost restructure core basis financing cost chf billion drive low interest expense financial chf million relate site closure employee spend small plan division chf million income chf million include net income equity security chf million offset net foreign include cost relate certain project exchange loss chf million ifrs tax expense chf billion increase core tax expense increase chf billion group effective core tax rate compare largely defer site consolidation pharmaceutical division announce strategic realignment manufacturing network include tax impact arise tax rate change exit manufacturing site clarecastle ireland legans spain segrate italy florence cost plan chf million chf million noncash writedown accelerate depreciation property plant equipment chf million relate site closure cost reorganisation cost employee cost divestment net income earning share nutley site complete second half result increase provision environmental remediation ifrs net income increase chf term cer dilute eps increase chf term cer core net income increase core eps cer core basis exclude noncore item global restructuring cost global restructuring plan major item chf million pharmaceutical division research development amortisation impairment goodwill intangible asset alliance business combination cost core ep increase strategic realignment chf million informatic mainly outsource function share service centre external exclude positive impact change group swiss pension plan provider detail give note annual financial statement roche finance report roche finance report roche group financial review financial review roche group net income net debt chf billion decrease chf billion free cash flow chf billion largely dividend payment chf billion net pension liability decrease chf billion improved asset performance additional change change chf chf chf cer pension contribution offset impact low discount rate region net tax liability decrease ifrs net income main factor defer tax effect impairment intangible asset decrease net pension liability equity compensation plan variable accord price underlie equity reconcile item net tax global restructuring plan intangible asset amortisation free cash flow goodwill intangible asset impairment alliance business combination free cash flow legal environmental case change change major debt restructuring chf chf chf cer pension plan settlement pharmaceutical normalisation equity compensation plan tax benefit diagnostic core net income corporate operating free cash flow supplementary net income ep information give page include calculation core eps reconcile treasury activity core result group publish ifrs result taxis pay free cash flow definition free cash flow detailed breakdown page financial position group operate free cash flow remain strong chf billion decrease relative occur growth financial position cash generation business offset high capital expenditure increase net work capital high investment intangible asset free cash flow chf billion decrease compare low operate free cash flow change change chf chf chf cer high pension contribution group refine calculation free cash flow exclude dividend line peer pharmaceutical group comparative free cash flow information restate accordingly impact operate free cash flow net work capital change longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset compare start year swiss franc depreciate significantly japanese yen dollar brazilian real result positive translation impact balance sheet position positive dollar translation impact net operating asset offset group level natural hedge group dollardenominate debt exchange rate give pharmaceutical division net work capital stable cer increase trade receivables line sale growth underlie inventory level remain stable overall exclude final unwind esbriet inventory fair value adjustment increase inventory launch preparation offset inventory writedown payable increase result conversion vendor extend payment term longterm net operating asset low mainly amortisation impairment compound acquire seragon acquisition diagnostic increase net work capital cer drive increase inventory high demand emerge market preparation new launch trade receivable increase sale growth asiapacific latin america region payable increase end result optimisation measure longterm net operating asset increase mainly continue capital expenditure roche finance report roche finance report roche group financial review financial review roche group pharmaceutical division operating result growth franchise result increase demand perjeta herceptin combination therapy continue uptake kadcyla sale increase immunology mainly come increase use actemraroactemra europe xolair esbriet sale mabtherarituxan sale continue grow especially china germany avastin sale pharmaceutical division operating result stable low sale offset growth international region particularly china sale notably mabthera rituxan herceptin negatively impact increase reserve mandatory discount hospital drug change change chf chf chf cer discount program ifrs result sale product sale royalty operating income cost sale pharmaceutical division sale marketing distribution change sale sale research development chf chf cer general administration oncology operating profit avastin margin sale herceptin mabtherarituxan core result perjeta sale tarceva royalty operating income kadcyla cost sale xeloda marketing distribution gazyvagazyvaro research development general administration total oncology core operate profit margin sale immunology actemraroactemra financial position xolair net work capital mabtherarituxan longterm net operating asset esbriet net operating asset cellcept pulmozyme free cash flow operate free cash flow total immunology margin sale infectious disease page definition core result core ep tamiflu valcytecymevene rocephin sale overview pegasys pharmaceutical division sale therapeutic area total infectious disease change sale sale therapeutic area chf chf cer ophthalmology oncology lucentis immunology total ophthalmology infectious disease ophthalmology neuroscience neuroscience madopar therapeutic area total sale total neuroscience pharmaceutical division sale increase cer chf billion lead growth oncology immunology product sale therapeutic area growth primarily drive perjeta herceptin actemraroactemra mabtherarituxan esbriet xolair product activasetnkase contribute chf billion cer sale growth sale pegasys tarceva lucentis decline total chf billion mircera competitive pressure sale valcytecymevene decrease generic competition recently launch product neorecormonepogin alecensa tecentriq cotellic add chf billion sale total therapeutic area total sale total mabtherarituxan sale chf million chf million split oncology immunology franchise roche finance report roche finance report roche group financial review financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma rheumatoid avastin advance colorectal breast lung kidney cervical ovarian cancer relapse glioblastoma type brain tumour arthritis certain type ancaassociate vasculitis avastin regional sale mabtherarituxan regional sale change sale sale chf chf cer change sale sale chf chf cer united states united states europe europe japan japan international international total sale total sale demand avastin continue robust sale remain stable overall sale decrease result grow use sale higher drive primarily growth china oncology immunology sale new immunotherapy agent lung cancer set europe sale stable growth come increase treatment negatively impact high discount hospital drug discount program sale europe increase ovarian colorectal lung cervical cancer sale negatively impact delist avastin france certain mainly come sale growth germany france sale growth japan mainly increase market share reflect indication sale international region grow mainly drive increase market access china south korea approval additional dosage administration nonhodgkin lymphoma maintenance therapy inflationary price increase argentina japan sale decrease negative impact biannual government price cut partially offset volume growth franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin actemraroactemra rheumatoid arthritis systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis herceptin regional sale actemraroactemra regional sale change sale sale change sale sale chf chf cer chf chf cer united states united states europe europe japan japan international international total sale total sale sale increase growth region especially drive increase demand subcutaneous formulation perjeta regional sale represent total actemraroactemra sale monotherapy change sale sale chf chf cer xolair moderate severe persistent allergic asthma chronic idiopathic urticaria ciu united states europe xolair regional sale japan change sale sale international chf chf cer total sales united states total sale kadcyla regional sale sale increase high prescription allergic asthma follow new approval use child continue uptake chronic idiopathic urticaria change sale sale chf chf cer united states lucentis wet agerelate macular degeneration wet amd macular oedema follow retinal vein occlusion rvo diabetic europe macular oedema dme japan international lucentis regional sale total sale change sale sale chf chf cer overall growth franchise herceptin sale grow continued growth result long united states duration treatment combination perjeta early advanced breast cancer herceptin sale total sale negatively impact drug discount program europe herceptin sale continue grow especially germany demand herceptin international region mainly drive china perjeta sale increase sale lucentis decline competition wet amd dme segment region particularly europe approve use surgery earlystage aggressive breast cancer kadcyla sale growth mainly drive international region europe notably germany japan franchise grow overall especially kadcyla particular secondline treatment perjeta firstline treatment herpositive metastatic recurrent breast cancer roche finance report roche finance report roche group financial review financial review roche group tarceva advanced nonsmall cell lung nsclc pancreatic cancer europe sale growth perjeta actemraroactemra mabtherarituxan herceptin growth partially offset continue price pressure region sale germany grew lead franchise avastin mabtherarituxan tarceva regional sale sale grow governmental tamiflu order negatively impact cancer drug fund delist avastin certain indication change sale sale chf chf cer united states japan sale grow despite government price cut negative effect sale approximately growth europe drive tamiflu alecensa sale growth come osteoporosis medicine edirol actemraroactemra japan franchise mabtherarituxan partially offset low sale femara neutrogin oxarol international total sale international sale increase drive asiapacific latin america region sales china grow additional provincial reimbursement herceptin avastin mabtherarituxan sale growth south korea come increase sale sale low decline sale europe international region increase competitive pressure avastin franchise sale growth latin america drive inflationary price increase argentina mexico sale decline mainly drive local loss exclusivity valcytecymevene xeloda sales growth turkey tnkaseactivase acute ischemic stroke ais acute myocardial infarction ami come franchise tnkaseactivase regional sale pharmaceutical division sale lead emerge market change sale sale change sale sale chf chf cer country chf chf cer united states brazil international china total sale india mexico sale higher lead growth mainly drive update prescribe information patient russia treat south korea turkey esbriet idiopathic pulmonary fibrosis ipf total sale esbriet regional sale change sale sale chf chf cer competition generic medicine biosimilar united states europe group pharmaceutical product generally protect patent right intend provide group exclusive international marketing right country patent right vary scope duration group required enter total sale costly litigation enforce patent intellectual property right loss market exclusivity major product patent expiration challenge generic medicine biosimilar noncomparable biologic reason continue uptake esbriet sale growth europe drive mainly spain italy material adverse effect group business result operation financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically result significant reduction net sale pharmaceutical division sale region relevant product manufacturer typically offer version low price change sale sale region chf chf cer patent expiry integral group business model future growth remain drive united states innovation late information clinical study include annual report page detail group europe product development portfolio available download japan httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm international eemea product sale affect recent patent expiry latin america change asiapacific chf chf cer comment region valcytecymevene patent expiry major market total sale recent approach patent expiry andor major market pegasys tamiflu impact eastern europe middle east africa sales products united states sale grew lead new indication xolair growth recently launch product esbriet intellectual property biologic involve multiple patent patent timeline individual product tecentriq alecensa franchise growth drive long duration combination treatment herceptin difficult exact date patent expiry biologic medicine group currently estimate basic primary perjeta sale lucentis fall competitive pressure avastin sale decrease result grow use new patent major biologic medicine begin expire follow immunotherapy agent lung cancer setting addition tamiflu sale decline weak influenza season high mabtherarituxan mid mandatory discount hospital drug discount program affect mabtherarituxan herceptin sale particularly herceptin avastin subcutaneous formulation mabtherarituxan herceptin secondary patent right roche finance report roche finance report roche group financial review financial review roche group patents mabtherarituxan herceptin expired base publicly available information competitor pharmaceutical division research development company group currently anticipate biosimilar version biologic medicine come market europe change onwards uncertainty surround specific biosimilar version group biologic medicine chf chf cer approve food drug administration research development core basis global restructuring plan amortisation intangible asset operating result impairment intangible asset total ifrs basis pharmaceutical division royalty operating income core cost increase cer percentage sale increase compare oncology change chf chf cer franchise remain primary area research development notably cancer immunotherapy latestage development growth royalty income mainly oncology earlystage research development expense increase related oncology immunology addition income outlicense agreement pharmaceutical division spend chf million chf million inlicense pipeline compound technology income disposal product capitalise intangible asset global restructuring cost mainly come strategic realignment research total ifrs core basis development area significant impairment charge relate decision stop development compound acquire seragon acquisition follow clinical datum assessment delay development compound acquire decrease cer low royalty income low income outlicense agreement royalty income fall trophos acquisition portfolio reassessment compound comparative period include certain significant royalty income addition certain patent expire royalty agreement partly offset increase sale party royaltybeare product decrease pharmaceutical division general administration outlicense income income commercialisation mircera collaboration partner change deblocke amendment income product disposal operating income increase high profitshare income chf chf cer mainly result high xolair sale europe product divestment xenical administration pension past service cost pharmaceutical division cost sale gain loss disposal property plant equipment business taxis capital taxis change chf chf cer general item manufacturing cost good sell period cost general administration core basis royalty expense global restructuring plan collaboration profitshare agreement impairment goodwill intangible asset impairment property plant equipment alliance business combination cost sale core basis legal environmental case global restructuring plan pension settlement gain loss amortisation intangible asset total ifrs basis business combination inventory fair value adjustment total ifrs basis core cost decrease cer percentage sale decrease mainly income change group swiss pension plan half exclude core cost increase impairment charge core cost increase cer percentage sale cost sale decrease percentage point manufacture writeoff goodwill anadys acquisition alliance business combination income come partial cost sale grow ahead sale growth pharmaceutical division considerable investment reversal contingent consideration provision seragon trophos acquisition biologic manufacture network recent year facility come line lead certain increase cost especially rampup phase temporary low utilisation small molecule manufacturing site transformation period additionally external contract manufacturer product flexibility security supply chain roche pharmaceutical chugai subdivisional operating result writedown inventory high royalty expense low expiry royaltybeare patent include avastin herceptin noncore cost include amortisation intangible asset mainly relate intermune pharmaceutical subdivisional operating result million chf acquisition final unwind inventory fair value adjustment acquire esbriet inventory global restructuring cost roche pharmaceutical mainly manufacture strategic realignment initiative announce pharmaceutical chugai division pharmaceutical division marketing distribution sale external customer change chf chf cer division marketing distribution core basis core operating profit global restructuring plan margin sale external customer amortisation intangible asset operate profit total ifrs basis margin sale external customer operate free cash flow core cost increase cer percentage sale rise slightly cost incur ensure margin sale increase patient access launch tecentriq ocrevus alecensa venclexta product restructuring cost relate pharmaceutical division total core operating profit operating profit include elimination minus chf million unrealised intercompany gain productivity initiative mainly asiapacific region roche pharmaceutical chugai chf million roche finance report roche finance report roche group financial review financial review roche group increase exchange rate japanese yen positive impact approximately chugai result express free cash flow swiss franc japanese yen sale external customer chugai increase sale division line chugai core operating profit decrease low gross profit sale division low milestone income pharmaceutical division operate free cash flow high research development cost partially offset high gross profit sale external customer low marketing change change distribution cost operate free cash flow chugai decrease capital expenditure project manufacturing chf chf chf cer research low operating profit operating profit depreciation amortisation impairment financial position provision equity compensation plan pharmaceutical division net operating asset operate profit cash adjustment movement movement change change transaction cta chf chf chf cer chf chf operating profit net operating cash adjustment trade receivables increase decrease net work capital inventory investment property plant equipment trade payable investment intangible asset net trade work capital operate free cash flow receivablespayable sale net work capital definition free cash flow detailed breakdown page property plant equipment pharmaceutical division generate operate free cash flow chf billion underlying cash generation remain strong goodwill intangible asset show decrease drive high capital expenditure increase net work capital high investment provision intangible asset new asset deal increase net work capital come inventory increase longterm asset net spending launch preparation trade receivables grow line sale positive impact longterm net operating asset operate free cash flow low yearend balance main item capital expenditure drive project switzerland germany chugai describe financial position section investment intangible asset include net operating asset inlicense pipeline compound technology asset deal absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc depreciate significantly japanese yen dollar brazilian real result positive translation impact net operating asset exchange rate give net work capital increase trade receivables line sale growth inventory level overall remain stable compare end exclude final unwind chf million esbriet inventory fair value adjustment increase inventory launch preparation offset inventory writedown payable increase end result conversion vendor long payment term longterm net operating asset overall longterm net operating asset low property plant equipment increase manufacturing investment switzerland germany chugai site development continue switzerland basel kaiseraugst site south san francisco campus line site master plan decrease intangible asset mainly amortisation impairment compound acquire seragon acquisition provision decrease reversal contingent consideration provision utilisation restructure provision mainly relate restructuring division manufacture network roche finance report roche finance report roche group financial review financial review roche group diagnostic division operating result centralise point care solution increase sale business area major contributor divisional performance region sale growth primarily drive immunodiagnostic business represent divisional sale support clinical chemistry business centralise point care solution business diagnostic division operating result grow asiapacific region increase sale china growth europe middle east africa emea region mainly immunodiagnostic change change chf chf chf cer ifrs result centralise point care solution regional sale sale change sale sale royalty operating income chf chf cer cost sale europe middle east africa emea marketing distribution north america research development rest world general administration total sale operating profit margin sale diabetes care sale decrease primarily fall north america sale major factor continue core result spill medicare price reduction commercial health plan lower demand reimbursement sale reduction canada blood glucose monitor portfolio sale development emea mainly decline royalty operating income germany middle east partially offset growth russia sale growth latin america new tender volume cost sale growth local inflationary effect marketing distribution research development diabetes care regional sale general administration change sale sale core operating profit chf chf cer margin sale europe middle east africa emea north america financial position rest world net work capital total sale longterm net operating asset net operating asset molecular diagnostic sale rise growth underlie molecular business growth sequence free cash flow business growth molecular business come virology business sale blood screening business operate free cash flow increase partly offset sale decline biochemical reagent business follow outsourcing distribution margin sale party sale sequence business grow follow ariosa kapa acquisition complete regionally growth drive north america asiapacific page definition core result core ep molecular diagnostic regional sale change sale sale sale chf chf cer europe middle east africa emea sale diagnostic division continue increase growth cer chf billion centralised point care solution north america name professional diagnostic make half division sale main contributor sale rest world growth lead immunodiagnostic business molecular diagnostic sale increase increase underlie total sale molecular business sale growth sequence business ariosa kapa acquisition complete diabete care sale decrease continued challenging market environment north america growth tissue diagnostic drive advanced stain product portfolio tissue diagnostic sale rise drive growth advance stain portfolio companion diagnostic sale grow addition sale grow primary stain business launch new instrument end diagnostic division sale business area regionally growth drive north america emea region growth drive advanced staining portfolio sale asiapacific grow china main market change sale sale business area chf chf cer centralise point care solution tissue diagnostic regional sale diabetes care change sale sale molecular diagnostic chf chf cer tissue diagnostic europe middle east africa emea total sale north america rest world total sale roche finance report roche finance report roche group financial review financial review roche group diagnostic division sale region diagnostic division marketing distribution change sale sale change region chf chf cer chf chf cer europe middle east africa emea marketing distribution core basis north america global restructuring plan asiapacific amortisation intangible asset latin america total ifrs basis japan total sale core cost increase cer primarily increased spending asiapacific region mainly china north america increase spend sequence business core basis marketing distribution cost percentage sale emea region division large market sale increase lead centralised point care solution molecular decrease compare global restructuring cost mainly reorganisation diabete care diagnostic sale growth north america drive centralised point care solution tissue diagnostic business partially offset decline diabetes care business impact continue pricing pressure sale increase asiapacific mainly china result increasingly broadbase medical insurance coverage public demand diagnostic division research development latin america sale increase new tender business local inflationary price increase sale growth japan change lead centralised point care solution business chf chf cer research development core basis diagnostic division sale lead emerge market global restructuring plan amortisation intangible asset change sale sale country chf chf cer total ifrs basis brazil china core cost increase cer drive spending genia ariosa acquisition sequence business india geneweave acquisition molecular diagnostic business key project limelight platform harmony test cobas mexico vivodx system contribute increase percentage sale research development core cost increase russia south korea turkey diagnostic division general administration total sale change chf chf cer administration operating result pension past service cost gain loss disposal property plant equipment diagnostic division royalty operating income business taxis capital taxis general item change chf chf cer general administration core basis royalty income global restructuring plan income outlicense agreement alliance business combination income disposal product legal environmental case total ifrs core basis pension settlement gain loss total ifrs basis decrease cer drive low royalty income notably molecular diagnostic base effect royalty payment expiry pcr technology patent core cost decrease cer income swiss pension plan change exclude core cost increase administration cost grow sequence business newly establish affiliate diabete care diagnostic division cost sale business business taxis decrease suspension medical device excise tax income general item reflect underspend infrastructure area percentage sale core cost decrease change chf chf cer manufacturing cost good sell period cost royalty expense cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis increase core cost come unfavourable product mix high instrument placement high cost external supplier core cost sale ratio increase compare global restructuring cost mainly relate site closure initiative harmonise process system roche finance report roche finance report roche group financial review financial review roche group financial position free cash flow diagnostic division net operating asset diagnostic division operate free cash flow change change movement movement chf chf chf cer change change transaction cta chf chf chf cer chf chf operating profit trade receivables inventory depreciation amortisation impairment trade payable provision net trade work capital equity compensation plan receivablespayable net work capital operate profit cash adjustment property plant equipment operating profit net operating cash adjustment goodwill intangible asset increase decrease net work capital provision investment property plant equipment longterm asset net investment intangible asset longterm net operating asset operate free cash flow sale net operating asset definition free cash flow detailed breakdown page absolute movement consolidated balance report swiss franc split actual transaction translate average operating free cash flow diagnostic division chf million compare chf million cash generation rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give business measure operating profit net operating cash adjustment increase cer improve annual financial statement reconciliation balance sheet information give operating result addition net work capital continue increase note comment financial position increase significantly high corresponding increase increase capital expenditure come expansion currency translation effect balance sheet amount compare start year swiss franc depreciate manufacturing site immunochemistry clinical chemistry product notably china germany capital dollar brazilian real result positive translation impact net operating asset diagnostic division project indianapoli site manufacture reagent new generation diabete care strip significant net asset position japanese yen depreciation swiss franc japanese yen minor development division headquarters switzerland partially offset low investment intangible asset compare impact exchange rate give period factor combine decrease division operate free cash flow relative net working capital net trade working capital increase cer trade receivables increase mainly sale growth asiapacific latin america region inventory increase high demand emerge market preparation new launch trade payable increase compare end result optimisation measure net liability receivablespayable increase increase employee benefit accrual longterm net operating asset increase cer increase property plant equipment decrease provision offset low intangible asset property plant equipment grow instrument placement manufacturing site expansion china germany site infrastructure development germany china switzerland provision decrease follow payment milestone relate acquisition decrease goodwill intangible asset mainly amortisation roche finance report roche finance report roche group financial review financial review roche group corporate operating result foreign exchange impact operating result corporate operating result summary group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment change chf chf cer administration growth report cer chf pension past service cost change cer change chf business taxis capital taxis general item pharmaceutical division general administration cost core basis sale global restructuring plan core operate profit alliance business combination legal environmental case diagnostic division total cost ifrs basis sale core operating profit financial position net work capital group longterm net operating asset sale net operating asset core operating profit free cash flow operate free cash flow exchange rate swiss franc page definition core result core eps general administration cost decrease cer core basis mainly income change group december average december average swiss pension plan exclude core cost decrease increase legal environmental cost come usd sale nutley site change net operating asset utilisation provision environmental remediation eur activity nutley grenzach germany corporate operating free cash flow show small outflow mainly gain jpy proceed nutley site compare swiss franc weak number currency particular japanese yen dollar euro appreciation major currency relevant group result total positive foreign exchange impact income statement compare negative impact sale development result positive impact percentage point equivalent chf billion currency translation gain operating profit percentage point mainly appreciation japanese yen dollar sensitivity group sale core operating profit change average foreign currency exchange rate swiss franc show table currency sensitivity impact change average exchange rate sale core operating profit versus swiss franc chf chf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany chugais revenues cost denominate japanese yen roche finance report roche finance report roche group financial review financial review roche group treasury taxation result financial income expense financial income expense net income chf million compare net expense chf million net income treasury taxation result equity security chf million chf million comparative period net foreign exchange result reflect hedging cost loss unhedged position net foreign exchange loss chf million compare net loss change change chf chf chf cer chf million result include foreign exchange loss chf million venezuela chf million ifrs result argentina analysis financial income expense give note annual financial statement operate profit financing cost financial income expense income taxis profit taxis income taxis group effective tax rate compare ifrs basis compare core basis net income largely defer tax impact result tax rate change ifrs result include noncore income attributable release contingent consideration provision taxable net tax effect alliance business roche shareholder combination line table positive impact offset unfavourable defer tax impact equity noncontrolle interest compensation plan core result analysis group effective tax rate operating profit financing cost profit income profit income financial income expense tax taxis tax rate tax taxis tax rate profit taxis chf chf chf chf income taxis group effective tax rate core basis net income global restructuring plan attributable goodwill intangible asset roche shareholder alliance business combination noncontrolle interest legal environmental case major debt restructure financial position treasury taxation normalisation equity compensation plan tax benefit net debt pension group effective tax rate ifrs basis income taxis financial noncurrent asset derivative net collateral net financial position interest payable nonoperate asset net net debt decrease chf billion free cash flow large dividend pay transaction equity instrument total net asset liability net pension liability decrease chf billion improved asset performance additional pension contribution offset low discount rate region net tax liability decrease mainly defer tax impact free cash flow treasury taxation impairment intangible asset partially offset defer tax effect decrease net pension liability defer tax treasury activity effect equity compensation plan variable accord price underlie equity december group taxis pay hold financial longterm asset market value chf billion consist holding biotechnology total pharmaceutical company acquire licensing transaction scientific collaboration compare start year swiss franc depreciate dollar negative translation impact group dollardenominate debt page definition core result core eps group refine calculation free cash flow exclude dividend line peer group free cash flow restate accordingly free cash flow financing cost cash outflow treasury activity increase chf billion additional pension contribution switzerland financing cost low ifrs basis loss comparative period chf million major debt ireland strategic investment partly offset low interest payment total taxis pay stable chf billion restructuring core financing cost chf billion decrease cer compare interest expense include group refine calculation free cash flow exclude dividend line peer group free cash flow amortisation debt discount issue cost decrease chf million continued repayment refinancing restate accordingly debt lead low weight average cost debt loss early redemption debt chf million compare chf million net interest cost define benefit pension plan increase cer chf million high discount rate germany end analysis financing cost give note annual financial statement detail debt repayment redemption give note roche finance report roche finance report roche group financial review financial review roche group cash flow net debt net debt million chf operate free cash flow billion chf free cash flow billions chf january cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow free cash flow millions chf dividend payment transaction equity instrument pharmaceutical diagnostic corporate group business combination net divestment subsidiary hedge collateral arrangement operate profit ifrs basis currency translation fair value movement operate profit cash adjustment change net debt operating profit net operating cash adjustment increase decrease net working capital december investments property plant equipment cash cash equivalent investment intangible asset marketable security operate free cash flow longterm debt treasury activity shortterm debt taxis pay net debt end period free cash flow definition net debt operating profit ifrs basis operate profit cash adjustment net debt currency profile millions chf operating profit net operating cash adjustment cash marketable security debt increase decrease net working capital investment property plant equipment dollar investment intangible asset euro operate free cash flow swiss franc treasury activity japanese yen taxis pay pound sterling free cash flow total definition free cash flow detailed breakdown page group refine calculation free cash flow exclude dividend line peer group free cash flow restate accordingly dollardenominated debt include bond note denominate euro swap dollar consolidated result economic characteristic equivalent dollardenominate bond note operate free cash flow decrease cer chf billion underlying cash generate operation increase chf billion offset high capital expenditure increase net work capital high investment intangible net debt position group december chf billion decrease chf billion december asset free cash flow largely annual dividend payment chf billion cash outflow treasury activity increase chf billion high pension contribution investment financial issuance redemption repurchase bond note note annual financial statement longterm asset partly offset low interest payment taxis pay stable chf billion free cash flow chf billion impact liquid fund impact net debt position low lower operate free cash flow high pension contribution group refine calculation free cash flow exclude dividend line peer group free cash flow restate accordingly result increase chf million free cash flow period impact operate free cash flow change roche finance report roche finance report roche group financial review financial review roche group contractual obligation commitment pension postemployment benefit group obligation commitment set table carry value show consolidated balance postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate sheet potential obligation show discount risk adjust foreign currency denominate amount fund thirdparty financial institution legal constructive obligation pay contribution translate swiss franc december exchange rate expense group define contribution plan chf million chf million plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually contractual obligation commitment december millions chf establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource potential obligation undiscounte carry year year year year total value onbalance sheet define benefit plan debt bond note operate income chf million record past service cost change group pension plan debt switzerland represent impact adjustment pension liability plan change exclude expense contingent consideration provision group define benefit plan chf million chf million base revise actuarial assumption end account payable expense group define benefit plan expect approximately chf million drive low discount derivative financial instrument rate begin estimate pension expense include settlement past servicecurtailment unfunded define benefit plan effect arise year total onbalance sheet commitment fund status balance sheet position offbalance sheet capital commitment property plant equipment chf chf operating lease fund plan contract manufacturing commitment fair value plan asset alliance collaboration commitment define benefit obligation total offbalance sheet commitment fund total contractual commitment unfunded plan define benefit obligation reference note consolidated financial statement total funding status debt consist mainly bond note include principal interest group debt instrument debt mainly commercial paper carry value discount base interest rate inherent instrument limit asset recognition reimbursement right contingent consideration provision potential payment arise business combination carry value risk net recognise asset liability adjust discount overall funding status ifrs basis group fund define benefit plan increase compare start unfunded define benefit plan mainly pension plan group german affiliate fully reserve pension year plan asset increase chf billion mainly drive high return asset additional contribution pay obligation invest local affiliate operation carry value discount future company contribution group pension plan switzerland ireland increase define benefit obligation arise decrease group fund plan show table discount rate region end offset change group swiss plan decrease define benefit obligation chf million fund status pension fund monitor local pension fund governance body capital commitment property plant equipment noncancellable commitment purchase construction closely review group level additional contribution pay group pension plan mainly roche site basel switzerland mannheim germany south san francisco chugai site switzerland ireland total cash outflow group define benefit plan chf million compare chf million operating lease future obligation noncancellable lease contract group implement ifrs lease point obligation report balance sheet unfunded plan mainly group german affiliate fully reserve pension obligation invest local affiliate operation unfunded liability plan increase chf billion decrease contract manufacturing commitment future minimum takeorpay commitment purchase inventory arise discount rate germany group major longterm agreement external contract manufacturing organisation cmos detail group pension postemployment benefit give note annual financial statement alliance collaboration commitment potential upfront milestone payment group inlicense arrangement potential payment alliance partner asset deal year include assume project currently development successful payment year time include asset deal provision legal environmental matter include table timing cash outflow uncertain contingent development matter question roche finance report roche finance report roche group financial review financial review roche group roche share information share nonvoting equity security change chf chf chf share price market capitalisation december eps basic eps diluted change chf core eps basic share price chf core eps diluted nonvoting equity security genussschein price chf equity attributable roche shareholder share market capitalisation billions chf dividend share roche rank number peer group consist roche healthcare company total shareholder detail refer note annual financial statement payout ratio calculate return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange dividend share divide core earning share rate cer roche rank number yearend return minus roche share minus roche nonvoting equity security combine performance share nonvoting equity security minus compare weight average return peer group chf term cer debt healthcare sector underperformed key market specific investor concern pricing pressure pricing reform election swiss market index underperform relative major global index investors reduce exchange rate exposure swiss equity drive strengthen dollar context despite positive news flow year strong late stage pipeline roche share overshadow anticipation key trial readout expect early debt redemption follow redemption uncertainty impact biosimilar early partial redemption usd million note originally march redeem march follow exercise earlycall option december peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck novartis pfizer redemption date march eur billion note roche sanofi takeda early redemption usd million note originally march redeem august follow exercise earlycall option june total shareholder return development addition december group complete tender offer repurchase usd million fix rate note march dec mar june sept dec debt issuance follow issuance february group issue eur million note february march group issue usd billion note october group issue usd million note january usd million note january transaction describe note annual financial statement roche share roche nonvoting equity security peer set index maturity schedule group bond note outstanding december show table bond note nominal amount december contractual maturity source datastream datum roche peer index rebase january peer index convert swiss franc daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer index dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf propose dividend board director propose increase dividend chf share nonvoting equity security chf approval annual general meeting consecutive increase dividend dividend total proposal approve shareholder dividend payment total share nonvoting equity security chf billion total translate december exchange rate chf billion result payout ratio base core net income base price yearend proceed bond note eur billion swap dollar consolidated result bond note economic dividend yield roche share yield nonvoting equity security characteristic equivalent dollardenominate bond note information roche security give page roche finance report roche finance report roche group financial review financial review roche group group plan meet debt obligation exist liquid fund cash generate business operation group enjoy strong longterm investmentgrade credit rating standard poor moodys time free cash flow chf billion include cash generate operation payment interest tax short roche rate high available shortterm rating agency event financing requirement rating overall term financing requirement group commercial paper programme issue usd billion creditworthiness roche group permit efficient access international capital market include commercial paper unsecured commercial paper note commit credit line usd billion available backstop line commercial paper market group commit credit line financial institution total chf billion chf billion serve note total usd billion outstanding december december usd billion longerterm financing backstop line commercial paper programme december debt draw credit line group maintain strong longterm investmentgrade credit rating standard poor moodys facilitate efficient access international capital market market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var information group debt give note annual financial statement assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var increase mainly gradual credit rating roche group december increase longterm interest rate major economy shortterm longterm outlook interest rate risk interest rate risk arise movement interest rate affect group financial result value moodys stable group equity group use interest rate derivative manage interestraterelated exposure financial result standard poor stable information financial risk management financial risk var methodology include note annual financial statement financial risk international financial reporting standard december group net debt position chf billion chf billion financial asset group manage conservative way objective meet group financial obligation time roche group international financial reporting standard ifrs report consolidated result group implement minor amendment exist standard interpretation material impact asset allocation considerable portion cash marketable security group currently hold debt group overall result financial position redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate cash marketable security material impact group overall result financial position chf total chf total group assess new revise standard mandatory summarise note cash cash equivalent annual financial statement detail money market instrument debt security ifrs financial instrument group plan implement new standard effective january group currently equity security anticipate comparative result restate new standard applied standard deal classification total cash marketable security recognition measurement include impairment financial instrument impairment financial asset include trade lease receivables introduce new hedge accounting model credit risk credit risk arise possibility counterpartie transaction default obligation cause financial ifrs revenue contract customer group plan implement new standard effective january loss group rating profile group chf billion cash fix income marketable security remain strong group anticipate new standard change amount revenue recognise invest aaaa range group sign net collateral agreement counterpartie order restatement necessary new standard contain new set principle recognise measure mitigate counterparty risk derivative position revenue new requirement relate presentation core principle framework revenue recognise dependent transfer promise good service customer reflect consideration group trade receivables chf billion begin financial difficulty southern european receive exchange good service country notably spain italy greece portugal group lead supplier healthcare sector country december trade receivables eur billion chf billion public customer country decrease ifrs lease group plan implement new standard effective january apply cumulative catchup compare december euro term substantial collection late group use different measure method option transition mean comparative result restate new standard apply improve collection country include intense communication customer forfaite negotiation payment plan main impact new standard bring operating lease onbalance sheet group assess potential impact charge interest late payment legal action strict commercial policy place select hospital greece italy currently anticipate new standard result carry value property plant equipment increase account hospital spain portugal closely monitor group trade receivable balance southern chf billion debt increase similar date implementation application new standard europe decrease eur term result currently report operating lease cost record interest expense give lease involve prevail low interest rate environment group currently expect effect material liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group good cash generation ability future cash flow repay debt instrument come year roche finance report roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group roche group roche group consolidated income statement year end december millions chf consolidated financial statement pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development roche group consolidated income statement year end december millions chf general administration operate profit pharmaceutical diagnostic corporate group sale financing cost royalty operating income financial income expense cost sale profit taxis market distribution research development income taxis general administration net income operating profit attributable financing cost roche shareholder financial income expense noncontrolle interest profit taxis earning share nonvoting equity security income taxis basic chf net income dilute chf attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group roche group consolidated statement comprehensive income millions chf roche group consolidate balance sheet million chf year end december december december december net income recognise income statement noncurrent asset property plant equipment comprehensive income goodwill remeasurement define benefit plan intangible asset item reclassify income statement defer tax asset define benefit plan asset availableforsale investment noncurrent asset cash flow hedge total noncurrent asset currency translation foreign operation item reclassified income statement current asset inventory comprehensive income net tax account receivable current income tax asset total comprehensive income current asset marketable security attributable cash cash equivalent roche shareholder total current asset noncontrolle interest total total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche finance report roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group roche group consolidate statement cash flow million chf roche group consolidate statement change equity million chf year end december non share retain fair value hedge translation control total cash flow operating activity capital earning reserve reserve reserve total interest equity cash generate operation year end december increase decrease net work capital january payment define benefit plan utilisation provision net income recognise income statement disposal product availableforsale investment operate cash flow cash flow hedge cash flow operating activity income taxis pay currency translation foreign operation income taxis pay remeasurement define benefit plan total cash flow operating activity total comprehensive income cash flow invest activity dividend purchase property plant equipment equity compensation plan net transaction purchase intangible asset equity disposal property plant equipment business combination disposal intangible asset change noncontrolle interest business combination equity contribution noncontrolle interest divestment subsidiary december interest dividend receive sale marketable security year end december purchase marketable security january invest cash flow total cash flow invest activity net income recognise income statement availableforsale investment cash flow financing activity cash flow hedge proceed issue bond note currency translation foreign operation redemption repurchase bond note remeasurement define benefit plan increase decrease commercial paper total comprehensive income increase decrease debt hedge collateral arrangement dividend change noncontrolle interest equity compensation plan net transaction equity contribution noncontrolle interest equity interest pay change noncontrolle interest dividend pay december equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group note roche group impairment december group chf million property plant equipment note chf million goodwill note chf million intangible asset note goodwill intangible asset available consolidated financial statement use review annually impairment property plant equipment intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate factor change discount rate plan use building machinery equipment closure facility presence competition technical obsolescence lower anticipate product sale lead short useful life impairment general accounting principle pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate basis preparation assumption december present value group define benefit obligation chf million note actuarial assumption differ materially actual result change market economic condition long consolidate financial statement annual financial statement roche group prepare short life span participant change factor assess difference impact define accordance international financial reporting standard ifrs comply swiss law prepare benefit plan asset liability recognise balance sheet future period historical cost convention item require account fair value approve issue board director january subject approval annual general meeting shareholder march legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate december group chf million legal provision status significant legal case financial statement annual financial statement roche holding ltd company register switzerland disclose note estimate consider specific circumstance legal case relevant legal advice inherently subsidiary group judgemental highly complex nature legal case estimate change substantially time new fact emerge legal case progress reliable estimate provision record contingent liability disclose group significant accounting policy change accounting policy disclose note material environmental provision group provide anticipate environmental remediation cost probable outflow key accounting judgement estimate assumption resource reasonably estimate december group chf million environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill preparation annual financial statement require management judgement estimate assumption affect treat contain contamination certain site estimate inherently judgemental uncertainty relate reported amount revenue expense asset liability contingent amount actual outcome differ detection previously unknown contamination method extent remediation percentage problematic management estimate estimate underlying assumption review ongoing basis base historical material attributable group remediation site financial capability potentially responsible party experience factor revision estimate recognise period estimate revise follow estimate change substantially time new fact emerge environmental remediation progress consider key accounting judgement estimate assumption believe appropriate base currently available information contingent consideration provision group make provision estimate fair value contingent consideration arrangement arise business combination december group chf million contingent consideration provision revenue nature group business sale transaction simple structure consist note total potential payment contingent consideration arrangement business combination multiple component occur different time group party outlicense agreement involve upfront milestone chf million note estimate amount provide expect payment determine consider possible payment occur year involve certain future obligation revenue recognise scenario forecast sale performance criterion pay scenario probability management judgement significant risk reward ownership transfer group retain scenario discount net present value estimate change substantially time new fact emerge continue managerial involvement effective control good sell obligation fulfil transaction scenario develop result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement circumstance level sale income taxis december group current income tax net liability chf million defer tax net asset return revenue reliably measure case sale recognise right return expire chf million note significant estimate require determine current defer tax asset liability generally prescription product patient order estimate management use publicly available information estimate base interpretation exist tax law regulation tax position uncertain accrual prescription information provide wholesaler intermediary record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience factor impact current defer taxis include change revenue product sale record net allowance estimate rebate chargeback cash discount estimate product tax law regulation rate change interpretation exist tax law regulation future level research development return establish time sale product sale allowance base estimate amount earn spending change pretax earning claim related sale december group chf million provision accrual expect sale return chargeback rebate include medicaid similar rebate country provision accrual relate lease treatment leasing transaction mainly determine lease consider operating finance pharmaceuticals business amount chf million chf million associate expect sale return lease make assessment management look substance lease legal form make judgement estimate consideration historical experience current contractual statutory requirement specific know market event substantially risk reward ownership transfer arrangement legal form trend competitive pricing new product introduction estimate inventory level shelf life product actual lease convey right use asset cover assessment future result vary estimate need adjust effect sale earning period adjustment december group chf million provision doubtful receivable note estimate base consolidation group periodically undertake transaction involve obtain control significant influence analyse age customer balance specific credit circumstance historical trend group experience take company transaction include equity acquisition asset purchase alliance agreement case management account current economic condition make assessment group control significant influence company consolidated subsidiary account associate company make assessment management consider business combination group initially recognise fair value identifiable asset acquire liability assume non underlie economic substance transaction addition contractual term control interest consideration transfer business combination management judgement particularly involve recognition fair value measurement intellectual property inventory contingent liability contingent consideration make assessment management consider underlie economic substance item concern addition contractual term roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group operating segment information pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division group division pharmaceutical diagnostic revenue primarily generate sale prescription revenue external customer pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale sale licensing product technology party residual operating activity divest business certain global royalty operating income activity report corporate include corporate executive committee global group function communication total human resource finance include treasury taxis pension fund management legal safety environmental service sub divisional information roche pharmaceutical chugai operate segment pharmaceutical division present revenue operate segment sale divisional information million chf royalty operating income elimination income division pharmaceutical diagnostic corporate group total revenue external customer sale segment result royalty operate income operating profit total elimination result division operate profit revenue operate segment sale capital expenditure royalty operating income business combination elimination interdivisional revenue addition property plant equipment total addition intangible asset total segment result operate profit research development research development cost capital expenditure elimination cost division business combination total addition property plant equipment addition intangible asset segment information total depreciation property plant equipment amortisation intangible asset research development impairment property plant equipment research development cost impairment goodwill impairment intangible asset segment information inventory fair value adjustment depreciation property plant equipment equity compensation plan expense amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset net operating asset millions chf inventory fair value adjustment asset liability net asset equity compensation plan expense pharmaceutical diagnostic corporate total operating nonoperating group roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group net operating asset pharmaceutical subdivisional information millions chf major customer asset liabilitie net asset total national wholesale distributor represent quarter group revenue national roche pharmaceutical wholesale distributor amerisourcebergen corp chf billion chf billion mckesson corp chf billion chugai chf billion cardinal health inc chf billion chf billion approximately revenue elimination division pharmaceutical operating segment residual diagnostic segment pharmaceutical division supplementary revenue information information geographical area millions chf revenue product sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount revenue external customer noncurrent asset earn claim related sale estimate consideration historical experience current contractual royalty property plant goodwill sale operate income equipment intangible asset statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust switzerland effect sale earning period adjustment germany rest europe grosstonet sale reconciliation pharmaceutical division show table company diagnostic europe division similar reconciling item low amount united states pharmaceutical division sale grosstonet reconciliation million chf rest north america north america gross sales latin america government regulatory mandatory price reduction contractual price reduction japan cash discount rest asia customer return reserve asia net sales africa australia oceania total government regulatory mandatory price reduction consist mandatory price reduction major element drug discount program medicaid plan total usd billion equivalent chf billion usd billion equivalent chf billion switzerland germany contractual price reduction include rebate chargeback result contractual agreement primarily rest europe volumebase performancebase europe cash discount include credit offer wholesaler remit payment purchase contractually define united states incentive period rest north america north america customer return reserve allowance establish expect product return latin america sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivable note sale reduction separately japan payable customer governmental health authority healthcare regulatory authority record balance sheet accrue rest asia liability note provision sale return record balance sheet provision note asia revenue royalties operating income millions chf africa australia oceania total royalty income supplementary unaudited information sale therapeutic area pharmaceutical division business area income outlicense agreement diagnostic division give financial review sale allocate geographical area destination accord location income disposal product customer royalty operating income allocate accord location group company receive total royalty operating income revenue income product disposal operating income include product divestment xenical income outlicensing arrangement include upfront milestone payment exclusive licence agreement galenica commercialisation mircera payment collaboration partner deblocke amendment roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group net financial expense income taxis finance cost millions chf income tax expense millions chf interest expense current income taxis amortisation debt discount defer taxis net gain loss debt derivative total income tax expense net gain loss redemption repurchase bond note loss major debt restructuring group operate internationally subject income taxis different tax jurisdiction group calculate average discount unwind expect tax rate weight average tax rate tax jurisdiction group operate rate change year net interest cost define benefit plan year change mix group taxable income change local tax rate total financing cost group average expect tax rate decrease main driver decrease low local tax rate japan low proportion group profit come tax jurisdiction high local tax rate average group tax rate financial income expense million chf group effective tax rate increase main driver increase defer tax impact tax rate change country defer tax impact respect equity compensation plan vary accord net gain loss sale equity security price underlie equity partially offset favourable impact release contingent consideration net gain loss equity security derivative provision taxable dividend income writedown impairment equity security group effective tax rate reconcile group average expect tax rate follow net income equity security reconciliation group effective tax rate interest income net gain loss sale debt security net interest income income debt security average expect tax rate net foreign exchange gain loss tax effect net gain loss foreign currency derivative nontaxable incomenondeductible expense foreign exchange gain loss equity compensation plan research development tax credit manufacturing deduction net financial income expense state tax impact tax unremitted earning associate utilisation previously unrecognised tax loss defer tax intragroup transfer total financial income expense prior year difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity net financial expense millions chf chf million chf million income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately chf million chf million record financing cost tax effect comprehensive income millions chf financial income expense net financial expense pretax aftertax pretax aftertax tax tax financial result treasury management remeasurement define benefit plan financial result pension management availableforsale investment associate cash flow hedge net financial expense currency translation foreign operation comprehensive income roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group income tax asset liability millions chf defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow current income taxis unrecognise tax loss expiry asset liability applicable applicable net current income tax asset liability chf tax rate chf tax rate year defer taxis year asset year liability total unrecognised tax loss net defer tax asset liability year category include loss state income tax purpose state current income tax liability include accrual uncertain tax position permit tax report separate entity basis current income taxis movement recognise net asset liability millions chf defer tax liability establish withholding tax taxis payable remittance earning foreign subsidiary amount currently regard permanently reinveste total unremitted earning group regard permanently reinveste chf billion december chf billion net current income tax asset liability january income taxis pay business combination charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect movement net current income tax asset liability december defer taxis movement recognise net asset liability millions chf property plant intangible define temporary equipment asset benefit plan difference total year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december year end december january charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december defer tax net asset temporary difference mainly relate accrue liability provision unrealise profit inventory roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group business combination identifiable asset acquire liability assume set table pharmaceutical acquisition net asset acquire millions chf acquisition trophos fmi total group complete business combination intangible asset product intangible use product intangible available use acquisition cash cash equivalent defer tax liability acquisition net asset acquire millions chf net asset liability net identifiable asset pharmaceutical diagnostic total noncontrolle interest intangible asset fair value previously hold equity interest product intangible use goodwill allocate foundation medicine product intangible available use goodwill allocate roche pharmaceutical marketing intangible use total consideration cash cash equivalent defer tax liability cash net asset liability contingent consideration net identifiable asset total consideration noncontrolle interest fair value previously hold equity interest fair value intangible asset determine excess earning method base management forecast goodwill observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted total consideration discount rate trophos fmi valuation perform independent valuer cash trophos goodwill represent control premium acquire work force synergy expect integrate contingent consideration acquire company group exist business goodwill expect deductible income tax purpose total consideration fmi goodwill represent strategic value roche pharmaceutical access fmis molecular information genomic analysis represent premium pay trade market price obtain control business acquire workforce pharmaceutical expect synergy goodwill expect deductible income tax purpose noncontrolle interest fmi measure date acquisition proportionate share fmis identifiable net asset trophos march group acquire control interest trophos privately own company base marseille france trophos report pharmaceutical division total consideration eur million eur million group recognise financial gain chf million fair valuing equity interest fmi hold group prior pay cash eur million arise contingent consideration arrangement contingent payment base transaction gain include financial income expense achievement performancerelate milestone range undiscounted outcome zero eur million impairment chf million record intangible asset acquire trophos acquisition note directly attributable transaction cost chf million report pharmaceutical operating segment general administration expense mainly relate fmi acquisition foundation medicine inc april group acquire control interest foundation medicine inc fmi publicly own company base cambridge massachusetts fmi list nasdaq stock code fmi fmi report impact trophos fmi acquisition result pharmaceutical division group material pharmaceutical division total cash consideration usd billion diagnostic ariosa diagnostics inc january group acquire control interest ariosa diagnostics inc ariosa privately own company base san jose california ariosa report diagnostic operating segment sequence business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million signature diagnostic february group acquire control interest signature diagnostic signature privately own company base potsdam germany signature report diagnostic operating segment sequence business total cash consideration eur million capp medical inc april group acquire control interest capp medical inc capp privately own company base palo alto california capp report diagnostic operating segment sequence business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group global restructuring plan geneweave biosciences inc august group acquire control interest geneweave biosciences inc geneweave privately own company base los gatos california geneweave report diagnostic operating segment molecular diagnostic business total consideration usd million usd million pay cash usd million arise contingent consideration arrangement contingent payment base group continue implementation major global restructuring plan initiate prior year notably achievement performancerelate milestone range undiscounted outcome zero usd million strategic realignment pharmaceutical division manufacturing network programme address longterm strategy diagnostic division kapa biosystems inc november group acquire control interest kapa biosystems inc kapa privately own company base wilmington massachusetts kapa report diagnostic operating segment global restructuring plan cost incur million chf sequence business total cash consideration usd million diagnostic site consolidation plan total identifiable asset acquire liability assume set table year end december global restructuring cost diagnostic acquisition net asset acquire millions chf employeerelate cost site closure cost ariosa signature capp geneweave kapa total reorganisation expense intangible asset total global restructuring cost product intangible use product intangible available use additional cost marketing intangible use impairment goodwill cash cash equivalent impairment intangible asset defer tax liability legal environmental case net asset liability net identifiable asset total cost goodwill total consideration year end december global restructuring cost cash employeerelate cost contingent consideration site closure cost total consideration divestment product business reorganisation expense fair value intangible asset determine excess earning method base management forecast total global restructuring cost observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate ariosa capp geneweave kapa valuation ariosa capp geneweave additional cost kapa perform independent valuer impairment goodwill impairment intangible asset goodwill represent control premium acquire work force synergy expect integrate acquire legal environmental case company group exist business goodwill expect deductible income tax purpose total cost directly attributable transaction cost chf million report diagnostic operating segment general include diabete care autonomy speed restructuring plan administration expense include pharmaceutical division strategic realignment manufacturing network include plan pharmaceutical division research development strategic realignment outsourcing impact ariosa signature capp geneweave kapa acquisition result diagnostic division group material diagnostic division cash flow business combination cost roche diabetes care autonomy speed initiative chf million chf million mainly consultancy itrelate matter employeerelate cost new strategy plan diagnostic diabetes care incur acquisition net cash outflow millions chf cost chf million related site closure employee spend small plan division chf million include cost relate certain project pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay deferred consideration pay contingent consideration pay cash acquire company transaction cost total net cash outflow roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group site consolidation global restructuring plan classification cost millions chf november pharmaceutical division announce strategic realignment manufacturing network include exit depreciation depreciation manufacturing site clarecastle ireland legans spain segrate italy florence cost plan amortisation amortisation chf million chf million chf million noncash writedown accelerate depreciation property impairment cost total impairment cost total plant equipment chf million chf million related site closure cost employee cost cost sale reorganisation expense divestment nutley site complete second half result pharmaceutical increase provision environmental remediation note diagnostic marketing distribution pharmaceutical global restructuring plan diagnostic research development total cost chf million major item chf million pharmaceutical division research pharmaceutical development strategic realignment chf million informatic mainly outsource function share service centre diagnostic external provider remain minor plan total chf million general administration pharmaceutical total cost chf million major item chf million pharmaceutical division research diagnostic development strategic realignment chf million initiative reduce field force europe asiapacific corporate region realignment april group sell wholly own subsidiary marcadia biotech inc party total loss disposal chf million remain minor plan total chf million total operating segment global restructuring plan summary cost incur millions chf roche pharmaceutical chugai diagnostic employeerelate cost corporate termination cost total define benefit plan employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost loss divestment subsidiary total cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group property plant equipment divestment nutley site september group complete divestment nutley site party previously announce property plant equipment movement carry value asset millions chf restructure total net consideration receive cash chf million divestment expect cost environmental remediation reassess accordingly environmental provision increase chf million note building land machinery construction land improvement equipment progress total january genentech property purchase option exercise cost accumulate depreciation impairment genentech enter master lease agreement mla slough ssf llc slough subsequently acquire net book value health care property lease property adjacent genentechs south san francisco site develop slough development include total building construction complete time genentech fully year end december occupy property property lease extension option november genentech exercise january purchase option contain mla acquire building land december group record addition business combination land building land improvement correspond liability cash outflow group addition reclassify finance lease accounting balance previously apply building november close payment disposal usd million reduce shortterm liability note final closing payment usd million transfer july record longterm liability note depreciation charge impairment charge leasing arrangement group lessee currency translation effect december finance lease december capitalise cost property plant equipment finance lease chf million chf million net book value asset chf million chf million carrying value leasing cost obligation chf million chf million report debt note accumulate depreciation impairment net book value finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value minimum lease year end december payment payment january business combination year addition year disposal year transfer total depreciation charge future finance charge impairment charge total future minimum lease payment undiscounte currency translation effect december operating lease group company party number operating lease mainly property rental motor vehicle arrangement impose significant restriction group total operating lease rental expense chf million cost chf million accumulate depreciation impairment net book value operating lease future minimum lease payment noncancellable lease million chf year classification impairment property plant equipment millions chf year year total minimum payment cost sale marketing distribution research development general administration leasing arrangement group lessor total impairment charge finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement impairment charge property plant equipment mainly relate global restructuring plan note asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group goodwill finance lease future minimum lease receipt noncancellable lease millions chf present value minimum gross investment lease lease receipt goodwill movement carry value asset millions chf year year year january total cost unearned finance income accumulate impairment unguaranteed residual value net book value net investment lease year end december accumulate allowance uncollectible minimum lease payment chf million chf million january business combination operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement impairment charge asset report property plant equipment lease income operating lease recognise lease term currency translation effect straightline basis december december machinery equipment original cost chf billion chf billion net book value cost chf billion chf billion lease party accumulate impairment net book value operating lease future minimum lease receipt noncancellable lease millions chf allocate follow cashgenerating unit roche pharmaceutical year foundation medicine year chugai year total pharmaceutical division total minimum receipt diabetes care centralise point care solution molecular diagnostic capital commitment tissue diagnostic sequence group noncancellable capital commitment purchase construction property plant equipment total strategic goodwill hold divisional level chf billion chf billion total diagnostic division impairment charge goodwill impairment charge chf million record pharmaceutical division writeoff goodwill anadys pharmaceuticals inc acquisition deem dispose impairment charge impairment goodwill impairment testing pharmaceutical division division operate segment cashgenerate unit test goodwill goodwill arise foundation medicine acquisition record monitor roche pharmaceutical level relate strategic development roche pharmaceutical cashgenerate unit strategic goodwill roche pharmaceutical recoverable impairment testing high value use fair value cost disposal chugai foundation medicine fair value cost disposal determined reference publicly quote share price chugai foundation medicine share roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group intangible asset diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable impairment intangible asset movement carry value asset millions chf testing base value use product product intangible marketing technology value use calculate discount expect cash flow approach posttax discount rate apply project intangible available intangible intangible riskadjuste posttax cash flow terminal value discount rate group weight average cost capital cash use use use use total generating unit integrate operation large part group derive capital asset pricing model datum january capital market include government twentyyear bond assess value use cash flow projection base cost recent business plan approve management business plan include management late estimate sale volume accumulate amortisation impairment pricing production operating cost assume significant change organisation key assumption net book value calculation period cash flow projection include business plan terminal value growth rate discount rate year end december january key assumption value use calculation business combination addition divestment subsidiary period terminal period terminal transfer cash flow value discount rate cash flow value discount rate projection growth rate tax projection growth rate tax amortisation charge pharmaceutical division impairment charge roche pharmaceutical year year currency translation effect diagnostic division december sequence year year diagnostic business year year cost accumulate amortisation impairment cashgenerating unit terminal value growth respective rate exceed longterm project growth rate net book value relevant market year period cash flow projection reflect longterm nature sequence business allocate operating segment roche pharmaceutical sensitivity analysis chugai diagnostic management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount total group rate combine decrease forecast cash flow chugai foundation medicine decrease publicly quote share price result sensitivity analysis demonstrate change key assumption year end december cause carrying value goodwill exceed recoverable december january addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group significant intangible asset december millions chf intangible asset impairment remain operating segment net book value amortisation period impairment charge arise change estimate future cash flow expect result use asset product intangible use eventual disposal factor presence absence competition technical obsolescence lower anticipate sale intermune acquisition roche pharmaceutical year product capitalise right result shorten useful life impairment foundation medicine acquisition roche pharmaceutical year ariosa acquisition diagnostic year kapa acquisition diagnostic year impairment charge iquum acquisition diagnostic year pharmaceutical division impairment charge total chf million record relate product intangible available use decision stop development compound acquire seragon acquisition follow clinical datum assessment trophos acquisition roche pharmaceutical chf million asset concern amortise fully write biontech licence transaction roche pharmaceutical delay development compound acquire trophos acquisition follow regulatory feedback chf million geneweave acquisition diagnostic asset concern amortise write estimate recoverable value chf million cmi acquisition diagnostic portfolio reassessment compound chf million asset concern amortise fully genia acquisition diagnostic write clinical datum assessment development project different alliance partner chf million asset concern technology intangible use amortise fully write dutalys acquisition roche pharmaceutical year decision stop development compound chf million asset concern amortise fully write diagnostic division impairment charge total chf million record relate classification intangible asset amortisation impairment expense million chf sequence product intangible use chf million result decision stop product development commercialisation license agreement alliance partner asset concern amortise fully write amortisation impairment tissue diagnostic product intangible use chf million result strategic portfolio reassessment asset concern cost sale amortise fully write pharmaceutical diagnostic marketing distribution impairment charge pharmaceutical diagnostic pharmaceutical division impairment charge total chf million record relate research development decision stop development compound different alliance partner chf million asset concern pharmaceutical amortise fully write diagnostic decision stop collaboration project alliance partner chf million asset concern amortise total fully write potential commitment alliance collaboration purchase agreement year internally generate intangible asset group party inlicense similar arrangement alliance partner intangible asset purchase agreement group currently internally generate intangible asset development criterion recognition asset party arrangement purchase agreement require group certain milestone similar payment meet dependent achievement agree objective performance target define collaboration purchase agreement group current estimate future thirdparty commitment payment year set table intangible asset indefinite useful life figure undiscounte riskadjuste meaning include potential payment arise assume project currently development successful timing base group current good estimate figure group currently intangible asset indefinite useful life include potential commitment group arise roche chugai business potential future thirdparty collaboration purchase payment december millions chf intangible asset available use pharmaceutical diagnostic group represent inprocess research development asset acquire inlicense arrangement business year combination separate purchase december approximately project pharmaceutical year division know decision point month certain circumstance lead impairment year inherent uncertainty research development process intangible asset available use particularly risk total impairment project expect result commercialise product roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group inventory marketable security inventory million chf marketable security millions chf raw material supply availableforsale financial asset work process equity security intermediate debt security finish good money market instrument time account month provision slowmove obsolete inventory investment total inventory total marketable security inventory expense cost sale total chf billion chf billion inventory writedown year marketable security hold fund management purpose primarily denominate swiss franc dollar euros result expense chf million chf million money market instrument contract mature year december debt security contract maturity million chf account receivable year year year account receivable million chf total debt security trade receivables note receivable receivables cash cash equivalent allowance doubtful account chargeback allowance withhold settlement total account receivable cash cash equivalent million chf allowance doubtful account movement recognise liability million chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent january additional allowance create unused amount reverse utilise year currency translation effect december bad debt expense record marketing distribution cost total chf million expense chf million roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group noncurrent asset account payable noncurrent asset millions chf account payable million chf availableforsale investment hold fair value trade payable availableforsale investment hold cost taxis payable loan receivable dividend payable longterm trade receivables payable restrict cash total account payable receivables total financial noncurrent asset longterm employee benefit asset noncurrent liability total nonfinancial noncurrent asset associate noncurrent liability millions chf total noncurrent asset availableforsale investment mainly equity investment private biotechnology company keep group defer income strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value longterm liability measure reliably total noncurrent liability longterm liability mainly relate accrued employee benefit longterm genentech property purchase option exercise obligation note current asset current liability current asset millions chf accrue interest income current liability millions chf derivative financial instrument restrict cash receivables defer income total financial current asset accrue payroll relate item interest payable prepay expense derivative financial instrument tax recoverable accrue chargeback allowance separately payable asset accrue royalty commission total nonfinancial current asset accrue liability total current liability total current asset december accrue liability include chf million shortterm genentech property purchase option exercise receivable mainly relate royalty licensing income receivables obligation pay november note roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group provision contingent liability environmental provision provision environmental matter include separate environmental issue number country nature amount provision movement recognise liability millions chf timing outflow difficult predict significant provision discount time value money material significant provision relate site nutley new jersey divest september legal environmental restructure employee provision provision provision provision provision total estimate remediation cost landfill site near grenzach germany manufacturing operation close year end december year ago estimate remediation cost manufacturing site clarecastle ireland divestment nutley january site expect cost environmental remediation reassess accordingly environmental provision increase additional provision create chf million unused amount reverse utilise discount unwind restructuring provision business combination acquire company arise plan programme materially change scope business undertaken group manner defer consideration business conduct provision include cost necessarily entail restructure associate contingent consideration recur activity group timing cash outflow reasonably certain provision discount movement time value money material matter currency translation effect december pharmaceutical division significant provision relate strategic realignment manufacturing network include exit manufacturing site note research development strategic alignment outsourcing function current share service centre external provider noncurrent december employee provision year end december january relate certain employee benefit obligation sabbatical leave longservice benefit timing cash additional provision create outflow reasonably estimate base past experience unused amount reverse utilise discount unwind provision business combination acquire company time cash outflow nature uncertain provision relate item show table defer consideration contingent consideration provision million chf movement currency translation effect december contingent consideration sale return current item noncurrent total provision december expect outflow resource year contingent liability year year operation earning group continue time time vary degree affect political legislative fiscal year regulatory development include relate environmental protection country operate industry december group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise legal provision company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment legal provision consist number separate legal matter include claim arise trade group company payment give note nature amount timing outflow difficult predict legal expense total chf million chf million reflect recent development legal matter detail major legal case outstanding disclose roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group pharmaceutical legal case tarceva subpoena november genentech receive subpoena department justice doj request document information relate promotion tarceva prescription product initially approve treatment locally december provision legal case pharmaceutical division chf million chf million provision advance metastatic nonsmall cell lung cancer failure prior chemotherapy regiman later approve record case settled mainly relate matter list additional indication genentech cooperate associate investigation government representative present time government civil liability theory specifically genentech allegedly participate offlabel promotion accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal tarceva cause submission false claim reimbursement civil false claim act august government action relate acne medication accutane litigation allege accutane cause certain closed criminal investigation genentech june genentech execute settlement agreement department condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder hlr justice state resolve civil investigation matter federal government state announce follow reevaluation portfolio medicine available generic manufacturer rapidly conclude decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product rituxan arbitration october genentech biogen idec inc file complaint california sanofiaventis deutschland gmbh sanofiaventis llc sanofiaventis inc sanofi seek declaratory judgment certain genentech product action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation mdl include rituxan infringe sanofis patent nos patent invalid sanofi district court middle district florida tampa division august mdl closed pendency allege rituxan genentech product infringe certain claim patent march district court mdl district court grant summary judgment favour hlr federal ibd case proceed rule matter law genentech biogen idec infringe assert patent claim sanofi appeal affirm court appeal eleventh circuit action pende state court new jersey allege ibd court noninfringement rule appellate court affirm district court judgment patent infringement consolidated pretrial proceeding superior court new jersey law division atlantic county addition october sanofi affiliate hoechst gmbh hoechst file icc international court arbitration paris january approximately case dismiss december approximately request arbitration genentech relate terminate patentlicence agreement hoechst predecessor dismiss case appeal hlr defend approximately action involve approximately plaintiff bring genentech pertain abovementione patent relate patent outside hoechst seek payment patent federal state court personal injury allegedly result use accutane licence royalty sale certain genentech product include rituxan damage breach contract relief arbitral award september february arbitrator find genentech liable hoechst patentlicence royalty february superior court new jersey law division atlantic county hold eightday evidentiary hearing rituxan award royalty interest hoechst seek february group record royalty expense plaintiff expert testify accutane cause crohns disease february superior court bar plaintiff expert chf million net assume reimbursement portion group obligation copromotion partner method meet requirement scientific reliability superior court enter order dismiss prejudice agreedupon list crohns disease case subject superior court february hoechst initiate proceeding france germany seek enforce arbitral awards october genentech pay order superior court enter order grant summary judgment dismiss case file new jersey award royalty interest hoechst protest genentech seek annulment arbitral award proceeding resident basis drug label adequate matter law july superior court grant hlrs initiate court appeal paris hearing proceeding june september paris court motion summary judgment adequacy label post ingestion case jurisdiction superior court appeal stay annulment proceeding seek guidance court justice specific legal question apply new jersey law jurisdiction grant hlrs motion dismiss approximately case alternative raise genentech relate arbitral award noncompliance competition law november hoechst file notice superior court apply home state law grant summary judgment jurisdiction deny jurisdiction appeal french supreme court seek review paris court appeal decision seek guidance court result case dismiss january october superior court enter order grant summary judgment justice november french supreme court deny hoechst challenge decision paris court appeal dismiss case failure prove accutane proximately cause ulcerative colitis plaintiff appeal refer specific legal question court justice july court justice issue opinion case find decision licensee freely terminate licence licence anticompetitive case proceed paris court appeal hearing expect half outcome matter determined time december juries new jersey superior court rule favour plaintiff case assess compensatory damage total usd million case rule favour plaintiff superior court case average wholesale price litigation hlr roche laboratories inc rli approximately brand generic settle seven case verdict reverse favour hlr usd million case usd million pharmaceutical company name defendant legal action relate pricing pharmaceutical appeal new jersey appellate division drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug superior court new jersey law division atlantic county schedule february evidentiary hearing price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state plaintiff expert testify accutane cause ulcerative colitis case survive hear additional trial schedule respective attorney general seek repayment amount claim overreimburse time period individual trial result depend variety factor include unique particular case trial associate case december hlr rli defend awp action file state result date predictive future trial result group continue defend vigorously remain personal injury case new jersey hlr rli vigorously defend trial date set outcome matter claim determine time avastinlucentis investigation february italian antitrust authority agcm announce investigation determine addition matter list currently provision record potential future obligation roche genentech novartis enter agreement restrict competition italian market drug confirm occurrence nonoccurrence uncertain future event obligation measure reference particular avastin market roche lucentis market novartis avastin lucentis different sufficient reliability drug develop approve different therapeutic purpose contain different active pharmaceutical ingredient march agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous order foster sale lucentis italy agcm fine roche eur million novartis eur million roche appeal legal action dismiss case canada relate postmenopausal osteoporosis medication boniva agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision litigation plaintiff allege boniva cause osteonecrosis jaw atypical femoral fracture december agcm roche strongly disagree verdict tar appeal italian ministry health notify roche defend approximately action involve approximately plaintiff bring federal state court roche spa intention seek damage relate matter july roche pay eur million fine protest personal injury allegedly result use boniva case early discovery stage litigation avoid additional penalty fee record expense general administration fine relate interest reimburse individual trial result depend variety factor include unique particular case roche vigorously defend roche win case outcome matter determine time matter outcome matter determine time roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group ema investigation october european medicines agency ema announce start infringement bond note procedure investigate allegation allege breach medicine safety report obligation relation centrally authorise medicine november ema announce result pharmacovigilance risk assessment committee recognise liability effective interest rate bond note millions chf assessment roche medicine ema find impact benefitrisk balance roche medicine effective interest rate confirm benefitrisk profile base available safety information ema health authority confirm underlying include medicine remain authorised change treatment advice patient healthcare professional corrective instrument hedge preventative action result inspection implement reinspection authority november lead dollar note fix rate certain finding roche address april ema issue report european commission note september principal usd billion summarise emas findings relation investigation july european commission issue notification isin usbc ema return case file ema new period inquiry july ema announce conclude note march principal usd billion second inquiry send july final update report european commission european commission isin usuam usas decide matter pursue financial penalty impose decision european commission note september principal usd billion isin usba matter pende outcome matter determine time note september principal usd billion isin usbb note january principal usd billion isin usbm note september principal usd billion isin usbe debt note november principal usd billion isin usbj note principal usd billion isin usbk note january principal usd billion isin usbl debt movement carry value recognise liability millions chf note march principal usd billion outstanding usd billion isin usuan usau note november principal usd billion isin usbh january proceed issue bond note dollar note float rate redemption repurchase bond note note september principal usd billion isin usbd increase decrease commercial paper note september principal usd billion isin usaz increase decrease debt net gain loss redemption repurchase bond note euro medium term note programme fix rate loss major debt restructuring note march principal gbp billion isin amortisation debt discount note march principal eur billion isin business combination note june principal eur billion isin net foreign currency transaction gain loss note march principal usd billion isin currency translation effect note march principal eur billion december outstanding eur billion isin note february principal eur billion isin bond note note august principal gbp billion commercial paper outstanding gbp billion isin amount bank financial institution note february principal eur billion isin finance lease obligation borrowing swiss franc bond fix rate total debt bond march principal chf billion isin bond september principal chf billion isin longterm debt bond september principal chf billion shortterm debt isin total debt genentech senior note pledge group asset connection debt senior note july principal usd billion isin usag senior note july principal usd billion outstanding usd billion isin usac total bond note roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group bond note maturity millions chf redemption repurchase bond note redemption dollar denominate note december group resolve exercise option early year partial redemption fix rate note march march group redeem outstanding principal year usd million equal sum present value remain schedule payment note discount year redemption date treasury rate plus accrue unpaid interest principal cash outflow year chf million plus accrue interest december group revise carrying value note account year change amount timing estimate cash flow result increase carry value usd million year chf million record financing cost note loss redemption additional total bond note chf million loss record redemption effective interest rate note june group resolve exercise option early partial redemption fix rate note march august group redeem outstanding principal usd million equal sum present value unamortised discount include carry value bond note millions chf remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow chf million plus accrue interest loss redemption chf million effective interest rate note dollar note euro note december group complete tender offer repurchase usd million fix rate note march swiss franc bond cash outflow chf million plus accrue interest loss repurchase chf million effective interest pound sterling note rate note total unamortised discount redemption euro note date march group redeem fix rate note principal eur billion cash outflow chf million plus accrue interest effective interest rate note issuance bond note redemption repurchase bond note february group issue eur million fix rate note coupon euro medium term note programme note mature february list luxembourg stock exchange group receive partial redemption dollar note december group resolve exercise option early partial chf million aggregate net proceed issuance sale fix note redemption fix rate note march march group redeem outstanding principal usd million equal sum present value remain schedule payment note discount march group complete offer usd billion fix rate note coupon note mature redemption date treasury rate plus accrue unpaid interest principal cash outflow group receive chf million aggregate net proceed issuance sale fix note chf million plus accrue interest additional chf million loss record redemption effective interest rate note october group complete offer usd million usd million fix rate note coupon respectively note mature january january respectively group receive september group complete tender offer repurchase usd million fix rate note march chf million aggregate net proceed issuance sale fix note cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note issuance bond note september group complete tender offer repurchase usd million fix rate note march cash outflow chf million plus accrue interest loss repurchase chf million effective interest february group issue eur billion fix rate note coupon euro medium term note rate note programme note mature february list luxembourg stock exchange group receive chf million aggregate net proceed issuance sale fix note redemption pound sterling note date march group redeem fix rate note principal gbp million cash outflow chf million plus accrue interest effective interest rate note march group issue usd million fix rate note coupon euro medium term note programme note mature march list luxembourg stock exchange group receive redemption genentech senior note date july group redeem fix rate senior note chf million aggregate net proceed issuance sale fix note principal usd billion cash outflow chf million plus accrue interest effective interest rate note november group complete offer usd billion fix rate note coupon note mature november group receive chf million aggregate net proceed issuance sale fix note partial repurchase genentech senior note september group repurchase usd million fix rate senior note july cash outflow chf million plus accrue interest loss repurchase major debt restructuring september group decide major debt restructuring group raise net proceed chf million effective interest rate note chf million debt offering describe newly issue debt senior unsecured guarantee roche holding ltd group repurchase usd million fix rate note march usd million fix rate partial repurchase euro note november group repurchase eur million fix rate note note march usd million fix rate genentech senior note july eur million fix march cash outflow chf million plus accrue interest loss repurchase chf million rate note march major debt restructuring result loss repurchase chf million effective interest rate note roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group equity attributable roche shareholder cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf change equity attributable roche shareholder millions chf reserve euro medium term note programme euro note retain euro medium term note programme dollar note share capital earning fair value hedge translation total dollar note year end december total cash inflow issuance bond note january net income recognise income statement cash outflow redemption repurchase bond note million chf availableforsale investment fair value gain loss take equity transfer income statement euro medium term note programme pound sterling note income taxis euro medium term note programme euro note noncontrolle interest dollar note cash flow hedge total cash outflow redemption repurchase bond note gain loss take equity transfer income statement income taxis noncontrolle interest commercial paper currency translation foreign operation exchange difference roche holdings inc commercial paper program roche holdings inc establish commercial paper program noncontrolle interest issue usd billion unsecured commercial paper note guarantee roche holding ltd total commit credit line define benefit plan available backstop support commercial paper program usd billion december maturity remeasurement gain loss note program exceed day date issuance december unsecured commercial paper note limit asset recognition principal usd billion average interest rate outstanding income taxis noncontrolle interest movement commercial paper obligation millions chf comprehensive income net tax total comprehensive income january net cash proceed payment dividend currency translation effect equity compensation plan net transaction equity december change noncontrolle interest december entire transfer income statement report financial income expense amount bank financial institution amount denominate currency notably chinese renminbi average interest rate december amount outstanding chf million chf million year roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group change equity attributable roche shareholder millions chf share capital reserve december authorise issue share capital roche holding ltd group parent company consist retain share capital earning fair value hedge translation total million share nominal value chf precede year share bearer share group year end december maintain register shareholder base information supply group shareholder group pool voting right owns january issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right net income recognise income statement hold share correspond share issue figure include share pooled voting right hold outside group individual member group maja oeri member pool availableforsale investment hold share represent voting right independently pool describe note base fair value gain loss take equity information supply group novartis hold basel own participation issue share transfer income statement income taxis noncontrolle interest cash flow hedge nonvoting equity security genussscheine gain loss take equity transfer income statement december nonvoting equity security authorise issue precede year income taxis swiss company law nonvoting equity security nominal value share capital noncontrolle interest issue contribution show asset balance sheet roche holding ltd nonvoting equity currency translation foreign operation security confer right share participate net profit remain proceed liquidation exchange difference follow repayment nominal value share participation certificate accordance law article noncontrolle interest incorporation roche holding ltd company entitle times exchange nonvoting equity security define benefit plan share participation certificate remeasurement gain loss limit asset recognition income taxis dividend noncontrolle interest comprehensive income net tax march shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribution holder outstanding share nonvoting equity securities total comprehensive income total chf million chf million record retain earning board director propose dividend business year chf share nonvoting equity security approve result dividend total distribution shareholder chf million subject approval annual general meeting march equity compensation plan net transaction equity change noncontrolle interest december equity instrument entire transfer income statement report financial income expense holding equity instrument equivalent number nonvoting equity security million millions genentech transaction share nonvoting equity security group complete purchase noncontrolle interest genentech effective march base international total accounting standard separate financial statement ias consistent international financial reporting standard consolidated financial statement ifrs adopt group transaction account equity instrument record equity original purchase cost december fair value share equity transaction consequence carrying consolidate equity group time reduce chf million nonvoting equity security chf billion equity instrument hold group potential conversion chf billion chf billion allocate eliminate book value genentech noncontrolle interest obligation arise group equity compensation plan note accounting effect significantly impact group net equity effect group business dividend policy reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group subsidiary license agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche chugai rest world umbrella right agreement exclude japan south korea sign revise amend effective october roche group chugai complete alliance create lead researchdriven japanese restate rest world umbrella right agreement exclude japan south korea taiwan sign august pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche agreement roche right refusal development marketing chugais development compound merge company know chugai market outside japan exclude south korea taiwan consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai agreement roche chugai sign series separate agreement certain specific product depend december roche relationship chugai found basic alliance license specific circumstance term agreement result payment arm length basis roche research collaboration agreement chugai follow matter upfront payment right refusal license product exercise common stock chugai publicly trade list tokyo stock exchange stock code tse chugai milestone payment dependent achievement agree performance target prepare financial statement accordance international financial reporting standard ifrs file quarterly basis royalty future product sale tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis chugai summarise financial information millions chf research collaboration agreement roche chugai enter research collaboration agreement area small molecule synthetic drug research biotechnologybase drug discovery income statement sale royalty operating income foundation medicine total revenue operate profit april group acquire control interest foundation medicine inc fmi enter investor right agreement research development collaboration agreement commercial collaboration agreement balance sheet noncurrent asset fmi fully consolidate subsidiary group base group interest fmi december current asset roche relationship fmi found agreement common stock fmi publicly trade noncurrent liability list nasdaq stock code fmi fmi prepare financial statement accordance gaap file current liability quarterly basis sec certain consolidation entry difference fmis standalone gaap result total net asset result fmi consolidated roche group accordance ifrs cash flow dividend dividend distribute party hold fmi share cash flow operating activity cash flow invest activity cash flow financing activity dividend dividend distribute party hold chugai share total chf million chf million record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group noncontrolle interest pension postemployment benefit change equity attributable noncontrolle interest millions chf group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation january fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial net income recognise income statement institution legal constructive obligation pay contribution plan classify define chugai benefit plan noncontrolle interest total net income recognise income statement define contribution plan availableforsale investment cash flow hedge define contribution plan fund payment employee group fund administer party currency translation foreign operation group expense plan chf million chf million asset liability recognise group remeasurement define benefit plan balance sheet respect plan apart regular prepayment accrual contribution withhold employee comprehensive income net tax wage salarie group contribution group major define contribution plan roche saving plan total comprehensive income define benefit plan business combination dividend noncontrolle shareholder plan usually establish trust independent group fund payment group company employee chugai case notably major define benefit plan germany plans unfunded group pay pension retire noncontrolle interest employee directly financial resource plan usually govern senior governing body board trustee equity compensation plan net transaction equity typically compose employee employer representative funding plan determine local regulation change noncontrolle interest independent actuarial valuation separate independent actuarial valuation prepare accordance requirement equity contribution noncontrolle interest ias use group financial statement group major pension plan locate switzerland germany december total account group define benefit obligation chugai pension plan switzerland current pension arrangement employee switzerland plan govern noncontrolle interest swiss federal occupational old age survivor disability pension act bvg group pension plan administer total noncontrolle interest separate legal foundation fund regular employee company contribution final benefit contributionbase certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility employee benefit operating income chf million record past service cost change group pension plan switzerland announce june represent impact adjustment pension liability plan change chf million record pharmaceutical division chf million diagnostic division employee remuneration millions chf chf million corporate past service income record general administration adjustment pension plan switzerland group payment chf million pension fund wage salarie pension plan group major define benefit plan close new member new social security cost employee join define contribution plan large remain define benefit plan fund pension plan define contribution plan include separate plan originate nutley palo alto indianapoli site small unfunded supplementary operating expense define benefit plan retirement plan benefit base high average annual rate earning specify period length equity compensation plan employment plan noncontributory employee group make periodic payment plan termination cost underfunding normally remedie additional company contribution payment group employee benefit usd million usd million increase contribution group benefit low insurance fee pension employee remuneration include operating result benefit guarantee corporation government agency oversee occupational pension scheme net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group pension plan germany group major pension arrangement germany govern occupational pension act define benefit plan fund status million chf betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan post post close new member replace new plan fund regular employee company pension employment pension employment contribution administer contractual trust agreement final benefit contributionbase minimum guarantee plan benefit plan total plan benefit plan total minimum guarantee plan treat define benefit plan purpose ifrs financial statement fund plan characteristic define contribution plan fair value plan asset define benefit obligation pension plan rest world represent approximately group define benefit obligation funding consist number small plan country large pension plan chugai independently unfunded plan manage chugai main pension plan united kingdom chugai plan fully describe chugais ifrs define benefit obligation financial statement pension plan fund regular employee company contribution benefit base final salary total funding status length employment plan close new member replace define contribution limit asset recognition plan group payment eur million pension fund ireland relation restructuring reimbursement right manufacturing site clarecastle net recognise asset liability postemployment benefit opeb plan represent approximately group define benefit obligation report balance sheet consist postretirement healthcare life insurance scheme mainly plan mainly unfunde define benefit plan asset contributory employee group reimburse retire employee directly financial resource group define benefit plan liability major opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient payment group plan december ifrs funding status include reimbursement right fund plan asset opeb plan responsibility investment strategy fund plan senior governance body board trustee asset define benefit plan income statement millions chf liability study perform regularly major pension plan study examine obligation postretirement benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select post post appropriate asset allocation fund hold plan investment strategy develop optimise expect return pension employment total pension employment total plan benefit plan expense plan benefit plan expense manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow current service cost asset plan obligation group currently use annuity longevity swap manage longevity risk past service income cost settlement gain loss plan asset manage internal external asset manager actual performance continually monitor pension total operating expense fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income net interest cost define benefit plan actual return plan asset gain chf million loss chf million total expense recognise income statement recognition pension asset limit present value economic benefit available refund plan reduction future contribution plan fund status define benefit plan fair value plan asset reimbursement right millions chf funding group define benefit plan responsibility senior governing body board trustee post post sponsor employer manage base local statutory valuation follow legislation requirement pension employment pension employment respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation plan benefit plan total plan benefit plan total regular basis actuarial assumption determine funding status statutory basis regularly assess local senior january govern body funding status closely monitor corporate level unfunded plan mainly group german interest income plan asset affiliate fully reserve pension obligation invest local affiliate operation remeasurement plan asset currency translation effect ifrs fund status fund define benefit plan improve employer contribution employee contribution reimbursement right link postemployment medical plan represent expect reimbursement benefit pay fund plan medical expenditure provide medicare prescription drug improvement modernization act benefit pay settlement administration cost december roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group define benefit plan composition plan asset millions chf define benefit plan define benefit obligation millions chf post post equity security pension employment pension employment debt security plan benefit plan total plan benefit plan total property january cash money market instrument current service cost investment interest cost december remeasurement demographic assumption asset invest variety different class order maintain balance risk return follow financial assumption equity debt security mainly quote market price level fair value hierarchy experience adjustment property mainly private commercial property fund mainly observable input level fair value currency translation effect hierarchy movement cash money market instrument mainly invest financial institution credit rating low employee contribution investment mainly consist alternative mortgage commodity insurance contract risk benefit pay fund plan management purpose mainly observable input level fair value hierarchy unobservable input level fair value benefit pay unfunded plan hierarchy benefit pay settlement past service income cost include fair value plan asset group share nonvoting security fair value chf million settlement gain loss chf million debt instrument issue group fair value chf million chf million december composition plan define benefit obligation active member defer vested member define benefit obligation calculate project unit credit method reflect service render employee retire member date valuation incorporate actuarial assumption primarily discount rate determine present value december benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond country plan geography deep market corporate bond corporate government bond denominate currency switzerland benefit pay maturity term approximate term relate pension obligation united states germany groups final salarybase define benefit pension plan germany united kingdom close new rest world participant active employee member pension plan time close new participant continue december accrue benefit final salarybase define benefit pension plan new employee join group define contribution plan new employee germany join contributionbase plan minimum guarantee result duration year proportion define benefit obligation relate closed plan expect decrease future define benefit pension plan switzerland final benefit contributionbase minimum guarantee remain open new employee actuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group demographic assumption significant demographic assumption relate mortality rate group actuary use mortality sensitivity analysis consider change assumption time leave assumption unchanged approach table account historic pattern expect change increase longevity rate employee show isolated effect change individual assumption account assumption relate turnover disability early retirement base historical behaviour average life expectancy assume individual method carry sensitivity analysis prior year age follow define benefit plan average life expectancy age major scheme year cash flow male female country mortality table group incur cash flow define benefit plan show table switzerland bvg projected cmi model united states project define benefit plan cash flow millions chf germany heubeck table bvg generational table employer contribution net reimbursement fund plan december mortality assumption pension plan switzerland base bvg apply benefit pay unfunded plan continuous mortality investigation cmi model group believe well reflect mortality improvement factor longterm rate total cash inflow outflow longevity improvement define benefit obligation measure mortality assumption approximately chf million low compare respective measure bvg generational table base recent actuarial valuation group expect employer contribution fund plan approximately chf million include estimate chf million additional contribution relate define benefit plan financial assumption base market expectation period obligation settle benefit pay unfunded plan estimate approximately chf million relate german define assumption actuarial valuation show benefit plan define benefit plan financial actuarial assumption weight weight equity compensation plan average range average range discount rate expect rate salary increase expect rate pension increase group operate equity compensation plan include separate plan chugai foundation medicine ifrs share expect inflation rate base payment require fair value equity compensation plan award grant employee estimate grant date immediate medical cost trend rate record expense vest period ultimate medical cost trend rate expense equity compensation plan millions chf discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase expect rate pension increase cost sale generally link expect inflation rate funding status plan expect inflation rate derive look level marketing distribution inflation imply financial market conjunction economist price inflation forecast historic price inflation research development economic variable circumstance medical cost trend rate account benefit set plan term general administration expect future change medical cost group major postemployment medical plan employee rate total operating expense drive development equity compensation plan sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate roche stocksettle stock appreciation right inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change roche restrict stock unit plan assumption present value define benefit obligation roche performance share plan roche connect define benefit plan sensitivity define benefit obligation actuarial assumption millions chf roche option plan bonus stock award chugai foundation medicine plan year increase life expectancy total operating expense discount rate increase decrease equitysettle expect inflation rate cashsettle increase decrease immediate medical cost trend rate increase decrease roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group cash inflow outflow equity compensation plan millions chf roche rsus movement number awards outstanding number award number award roche option plan exercise thousand thousand chugai foundation medicine plan exercise outstanding january roche connect cost grant transaction equity forfeit total cash inflow outflow equitysettle equity compensation plan transfer participant net transaction equity outstanding december vest transferable net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note roche performance share plan group offer future share nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equitysettle award equity compensation plan programme currently operate annual threeyear cycle roche performance share plan psp include value adjustment equivalent sum shareholder distribution group vest period attributable roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain number share nonvoting equity security individual award grant share nonvoting director management employee select discretion group ssar employee right receive non equity security allocate depend individual salary level achievement performance target link group vote equity security reflect value appreciation market price nonvoting equity security total shareholder return share nonvoting equity security combine relative group peer threeyear period grant date exercise date roche ssar plan million ssar available issuance tenyear period date grant discretion board director award result zero share non right nontradable equitysettle award sevenyear duration vest phase basis year vote equity security value adjustment depend achievement performance target roche ssar movement number right outstanding roche performance share plan term outstanding award december weight average weight average number award outstanding thousand number right exercise price number right exercise price thousand chf thousand chf vest period year year year outstanding january allocate recipients feb feb feb grant fair value unit grant chf forfeit total fair value grant chf million exercise expire outstanding december roche connect programme enable employee worldwide certain country exercisable regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan chf million chf million roche ssar term right outstanding december roche option plan programme country ssar award plan employee right right outstanding right exercisable purchase nonvoting equity security exercise price specify grant date option nontradable equity number weight average weight average number weight average settle award sevenyear duration vest phase basis year outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant total forfeit exercise expired roche restrict stock unit plan group issue restrict stock unit rsus award certain director management outstanding december employee select discretion group rsus nontradable represent right receive nonvoting equity exercisable security vest threeyear period subject performance condition currently performance condition outstanding rsus december roche rsu plan million nonvoting equity security available issuance tenyear period roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group earning share nonvoting equity security roche option plan term option outstanding december option outstanding option exercisable weighted average weighted average weight average basic earning share nonvoting equity security number outstanding year remain exercise price number exercisable exercise price year grant thousands contractual life chf thousand chf net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number share nonvoting equity security issue million total basic earning share nonvoting equity security chf weight average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number awards fair dilute earning share nonvoting equity security value award calculate grant date net income attributable roche shareholder chf million fair value measurement increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million input measurement fair value grant date equity compensation plan follow net income calculate diluted earning share chf million fair value measurement weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million roche stocksettle roche weight average number share nonvoting equity security issue stock appreciation roche restrict performance share roche option right stock unit plan plan plan calculate diluted earning share million progressively cliff vest cliff vest progressively vest period year year year year diluted earning share nonvoting equity security chf contractual life year year number grant year thousand weight average fair value chf model binomial market pricea monte carlob binomial input option pricing model share price grant date chf exercise price chf expect volatility expect dividend yield early exercise factor expect exit rate fair value roche rsus equivalent share price date grant input parameter covariance matrix roche individual company peer group base threeyear history riskfree rate minus valuation take account define rank performance structure determine payout plan volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group statement cash flow cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument cash flow operating activity include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow operating activity arise group primary activity pharmaceutical diagnostic business cash flow shortterm borrowing show net movement consist large number transaction short calculate indirect method adjust group operate profit operating income expense cash flow maturity example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity dividend pay millions chf cash generate operation million chf dividend roche group shareholder dividend noncontrolle shareholder chugai net income dividend noncontrolle shareholder add nonoperate income expense increase decrease dividend payable financing cost dividend withholding tax financial income expense total income taxis operate profit depreciation property plant equipment significant noncash transaction amortisation intangible asset impairment goodwill significant noncash transaction contingent consideration arrangement arise business impairment intangible asset combination note impairment reversal property plant equipment operating income expense define benefit plan significant noncash transaction contingent consideration arrangement arise business operating expense equitysettle equity compensation plans combination note genentech property purchase option exercise note net income expense provision bad debt reversal expense inventory writedown inventory fair value adjustment net gain loss disposal product adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group risk management nature geographic location counterpartie account receivable overdue impair show table include balance national wholesalers southern europe public customer describe group risk management account receivable overdue nature geographical location counterpartie millions chf risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor saler saler regularly discuss corporate executive committee audit committee board director region total public distributor private total public distributor private switzerland europe financial risk management north america latin america group expose financial risk arise underlie operation corporate finance activity group japan financial risk exposure predominantly relate change foreign exchange rate interest rate equity price asia australia oceania creditworthiness solvency group counterpartie rest world total financial risk management group govern policy review board director roche chugai foundation medicine appropriate area statutory responsibility policy cover credit risk liquidity risk market risk ageing account receivable impair show table policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday ageing account receivable impaired millions chf risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai foundation medicine overdue impair overdue month credit risk overdue month overdue month credit risk arise possibility counterpartie transaction default obligation cause financial loss overdue month group objective manage counterparty credit risk prevent loss liquid fund deposit invest overdue year counterpartie maximum exposure credit risk result financial activity consider net agreement total account receivable take account collateral hold credit enhancement equal carrying value group financial asset cash marketable security december group cash marketable security chf billion account receivable december group trade receivables chf billion chf billion subject chf billion subject policy restricting exposure highquality counterpartie set define limit policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation individual counterpartie limit counterparty credit rating review regularly investment marketable security account monitor procedure objective trade receivables management maximise collection unpaid amount enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure december group combine trade receivable balance national wholesale distributor amerisourcebergen individual financial institutions corp mckesson corp cardinal health inc equivalent chf billion represent group consolidated trade receivables chf billion represent significant concentration counterparty credit risk rate analysis cash fix income marketable security market value group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect chf total chf total collection trade receivables december collateral hold trade receivables aaarange aarange financial difficulty southern european country notably spain italy greece portugal group arange lead supplier healthcare sector country trade receivable chf billion chf billion bbbrange public private customer country group use different measure improve collection country bbbrange include intense communication customer factor negotiation payment plan charge interest late payment unrated legal action total master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment loss total impairment loss availableforsale financial asset amount chf million chf million roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group liquidity risk market risk liquidity risk arise surplus financial obligation available financial asset point time group market risk arise change market price mainly foreign exchange rate interest rate group financial asset approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time financial liability affect group financial result equity roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate committed credit line financial institution total chf billion chf billion chf billion serve value range give financial instrument fluctuate preset probability result movement market backstop line commercial paper program price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level holding period remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show trading day past year hold period reflect time require change correspond risk exposure table deem appropriate contractual maturity financial liability millions chf actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment carry value total year year year year price particularly period high market volatility furthermore var include effect change credit spread year end december debt market risk financial instrument millions chf bond note debt contingent consideration var interest rate component account payable var foreign exchange component derivative financial instrument var price component total financial liability diversification var total market risk year end december debt interest rate component increase mainly gradual increase longterm interest rate major economy foreign bond note exchange component remain largely stable price component arise mainly movement equity security price debt remain largely stable contingent consideration account payable derivative financial instrument foreign exchange risk total financial liability group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro objective group foreign exchange risk management activity preserve economic takeorpay commitment group enter contract manufacturing agreement company develop value current future asset minimise volatility group financial result primary focus group foreign manufacturing capacity flexibility future minimum takeorpay commitment agreement total exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position potential commitment group chf billion december chf billion mainly relate contract hold foreign currency group use forward contract foreign exchange option crosscurrency swap hedge transaction manufacturing agreement pharmaceutical division effect respectively exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc euro float rate financial instrument primary objective group interest rate management protect net interest result group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group price risk financial instrument accounting classification fair value price risk arise mainly movement price equity security group manage price risk place limit fair value financial asset liability carry value show consolidated balance sheet follow individual total equity investment limit define percentage total liquid fund absolute number individual equity investment carry value fair value financial instrument millions chf fair value total available hedge fair value loan financial carry capital management forsale instrument designate receivables liability value fair value year end december group define capital manage group total capitalisation sum debt plus equity include non noncurrent asset control interest group objective manage capital availableforsale investment safeguard group ability continue go concern continue provide benefit patient return financial noncurrent asset investor account receivable provide adequate return investor base level risk undertake marketable security available necessary financial resource allow group invest area deliver future benefit patient cash cash equivalent return investor current asset maintain sufficient financial resource mitigate risk unforeseen event derivative financial instrument financial current asset capitalisation report senior management group regular internal management reporting show total financial asset table debt capital million chf bond note debt contingent consideration capital reserve attributable roche shareholder account payable equity attributable noncontrolle interest derivative financial instrument total equity total financial liability total debt year end december noncurrent asset capitalisation availableforsale investment financial noncurrent asset group net equity significantly impact genentech transaction note account receivable marketable security group subject regulatory capital adequacy requirement know financial service industry group majority cash cash equivalent shareholding chugai foundation medicine note chugai foundation medicine public company current asset objective policy process manage capital determine local management derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability fair value bond note level calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group fair value hierarchy level fair value table analyse financial instrument carry fair value valuation method different level define follow detail determination level fair value measurement set level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability contingent consideration arrangement millions chf level unobservable input fair value hierarchy financial instrument millions chf january arise business combination level level level total utilise year end december total unrealised gain loss include income statement marketable security unused amount reverse equity security additional create debt security discount unwind include financing cost money market instrument time account month total gain loss include comprehensive income derivative financial instrument currency translation effect availableforsale investment hold fair value december financial asset recognise fair value derivative financial instrument contingent consideration contingent consideration arrangement financial liability recognise fair value group party certain contingent consideration arrangement arise business combination fair value determine year end december consider expect payment discount present value riskadjusted average discount rate marketable security expect payment determine consider possible scenario forecast sale performance criterion equity security pay scenario probability scenario significant unobservable input forecast sale debt security performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance money market instrument time account month criterion rate higher riskadjuste discount rate low december total potential payment contingent derivative financial instrument consideration arrangement chf billion chf billion follow availableforsale investment hold fair value financial asset recognise fair value potential payment contingent consideration arrangement millions chf derivative financial instrument acquisition year acquire operating segment contingent consideration seragon roche pharmaceutical financial liability recognise fair value trophos roche pharmaceutical dutalys roche pharmaceutical level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper santaris roche pharmaceutical certificate deposit derivative financial instrument genia diagnostic geneweave diagnostic group determine level fair value follow valuation technique cmi diagnostic marketable security derivative financial instrument base valuation model use observable market datum interest ariosa diagnostic rate yield curve foreign exchange rate imply volatility similar instrument measurement date diagnostic availableforsale investment base valuation model derive recently publish observable financial price december group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year derivative financial instrument group enter currency swap certain nonus dollar debt instrument cash collateral agreement enter counterpartie currency swap mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group derivative financial instrument millions chf undiscounte cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity asset liability foreign currency derivative expect cash flow qualify cash flow hedge impact profit loss million chf forward exchange contract crosscurrency swap total year year total year year interest rate derivative cash inflow swap cash outflow total cash inflow outflow derivative carry value derivative financial instrument change hedge reserve equity show note derivative subject master netting agreement collateral arrangement fair value hedge group enter interest rate swap hedge fixedterm debt instrument net december instrument record fair value liability chf million chf million fair value asset chf million chf million loss chf million record interest rate swap gain chf million fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument collateral arrangement net investment hedge group net investment hedge date march group redeem fix rate note principal eur billion result hedge terminate cash receive group counterpartie movement cash collateral receivable accrue liability million chf relate party january net cash deliver group control shareholder december share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own hedge accounting share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas december group follow cash flow hedge fair value hedge designate qualifying hedge duschmal charitable foundation wolf shareholder pooling agreement exist figure relationship include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euro pound sterling december instrument andr hoffmann andreas oeri members board director roche holding ltd hoffmann receive record net fair value liability chf million chf million ineffective portion remuneration totalling chf chf oeri receive remuneration totalling chf chf chugai enter foreign exchange forward contract hedge foreign translation exposure swiss franc transaction group individual member shareholder group exception dollar december instrument record fair value asset chf million fair value liability jrg duschmal work postdoc roche chf million ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration subsidiary associate derivative contract final settlement maturity show table list major group subsidiary associate include note transaction parent company expect cash flow qualify cash flow hedge millions chf subsidiary subsidiary eliminate consolidation significant transaction group associate total year year total year year cash inflow cash outflow total cash inflow outflow roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group key management personnel equity compensation plan member corporate executive committee receive equity compensation show follow table total remuneration key management personnel chf million chf million number right option award grant member corporate executive committee member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee franz members corporate executive committee cec roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance roche stocksettle stock appreciation right contribution respect remuneration pay contribution pension postemployment benefit plan roche restrict stock unit plan chairman board director member cec members cec participate certain equity compensation roche performance share plan plan describe term vest condition fair value award disclose note new member cec include table calendar year join cec similarly member cec retire way year include calendar year leave cec contribution pay member corporate executive committee millions chf remuneration member board director corporate executive committee millions chf roche connect salary include cashsettle bonus bonus stock award social security cost transaction member board director corporate executive committee pension total chf million pension postemployment benefit pay group corporate executive committee member chf million equity compensation plan board fee employee benefit define benefit plan total transaction group define benefit plan employee group describe note purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition subsidiary associate detailed disclosure executive remuneration require swiss law include remuneration report include annual report page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete list company performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel share capital equity interest country company city millions switzerland roche holding ltd basel chf reconciliation executive remuneration disclosure require swiss law millions chf stock exchange swiss exchange zurich valor share valor genussschein isin share total remuneration member board director corporate executive committee isin genussschein ifrs basis table market capitalisation chf japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo deduct isin bonus stock award ifrs basis market capitalisation jpy equity compensation plan ifrs basis united states foundation medicine inc cambridge usd add stock exchange nasdaq stock code fmi bonus stock award swiss legal basis market capitalisation usd equity compensation plan swiss legal basis total remuneration member board director corporate executive committee swiss legal basis include social security cost board director annual report corporate executive committee annual report bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group share capital equity interest nonliste company country company city millions france institut roche sas boulognebillancourt eur share capital equity interest roche diabetes care france sas meylan eur country company city million roche diagnostic france sas meylan eur algeria roche algrie spa hydra dzd roche sas boulognebillancourt eur argentina productos roche qumica industrial tigre ar trophos marseille eur roche diabetes care argentina tigre ar georgia roche georgia llc tbilisi gel vanguardia productos farmacuticos vanprofarma buenos aire ars germany ascur versicherungsvermittlung gmbh grenzachwyhlen eur australia roche diabetes care australia pty limited bella vista aud galenus mannheim pharma gmbh mannheim eur roche diagnostic australia pty limited castle hill aud roche beteiligung gmbh grenzachwyhlen eur roche product pty limited dee aud roche deutschland hold gmbh grenzachwyhlen eur austria dutalys gmbh vienna eur roche diabete care deutschland gmbh mannheim eur roche austria gmbh vienna eur roche diabetes care gmbh mannheim eur roche diagnostic gmbh vienna eur roche diagnostic deutschland gmbh mannheim eur azerbaijan roche azerbaijan llc baku azn roche diagnostic gmbh mannheim eur bangladesh roche bangladesh limited dhaka bdt roche diagnostic solution gmbh berlin eur belarus fllc roche product limit minsk usd roche mtm laboratories mannheim eur belgium roche brussels eur roche pharma grenzachwyhlen eur roche diagnostic belgium brussels eur roche pvt gmbh waiblingen eur bermuda chemical manufacturing trading company limit hamilton usd roche real estate service mannheim gmbh mannheim eur hoffmannla roche product limited hamilton usd signature diagnostic gmbh potsdam eur roche capital services ltd hamilton rub ghana roche product ghana limited accra ghs roche catalyst investments ltd hamilton usd greece roche hellas athens eur roche financial investments ltd hamilton usd roche diagnostic hellas athens eur roche financial management ltd hamilton usd guatemala producto roche guatemala guatemala gtq roche financial services ltd hamilton usd honduras producto roche honduras tegucigalpa hnl roche international ltd hamilton usd hungary roche hungary ltd budapest huf roche intertrade limited hamilton usd roche services europe ltd budapest huf roche operations ltd hamilton usd india roche diabete care india private limited mumbai inr roche services holdings ltd hamilton usd roche diagnostic india private limited mumbai inr syntex pharmaceuticals international ltd hamilton usd roche product india private limited mumbai inr bolivia roche bolivia srl santa cruz bob indonesia roche indonesia jakarta idr bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam iran roche par ltd tehran irr brazil produto roche qumico farmacuticos paulo brl ireland roche ireland limited clarecastle eur roche diabete care brasil ltda paulo brl roche product ireland limited dublin eur roche diagnostica brasil ltda paulo brl israel medingo ltd yoqneam illit il bulgaria roche bulgaria eood sofia bgn roche pharmaceutical israel ltd hod hasharon il cameroon roche cameroun sarl douala xaf italy roche diabetes care italy spa monza eur canada chempharm limited mississauga cad roche diagnostic spa monza eur hoffmannla roche limited mississauga cad roche spa monza eur sapac corporation ltd hamilton cad japan roche japan tokyo jpy chile roche chile limitada santiago chile clp roche diagnostic tokyo jpy china roche china holding ltd shanghai usd jordan hoffmannla roche ltd jordan psc amman jod roche diagnostic hong kong limited hong kong hkd kazakhstan roche kazakhstan llp almaty kzt roche diagnostic shanghai limited shanghai usd kenya roche kenya limited nairobi ke roche diagnostic suzhou limited suzhou usd latvia roche latvija sia riga eur roche hong kong limited hong kong hkd lebanon roche lebanon sarl beirut lbp roche center china ltd shanghai usd lithuania uab roche lietuva vilnius eur shanghai ien pharma ltd shanghai cny macedonia roche makedonija dooel skopje eur shanghai roche pharmaceuticals limited shanghai usd malaysia roche malaysia sdn bhd kuala lumpur myr colombia producto roche bogot cop roche diagnostic malaysia sdn bhd petale jaya myr costa rica roche servicios heredia usd roche services asia pacific sdn bhd kuala lumpur myr cte divoire roche cte divoire sarl abidjan xof syntex pharmaceuticals sdn bhd kuala lumpur myr croatia roche doo zagreb hrk mauritius roche product mauritius ltd quatre borne mur czech republic roche sro prague czk mexico productos roche mexico city mxn denmark roche medicinalvarer kemikalier hvidovre dkk roche servicios mxico mexico city mxn roche diagnostic hvidovre dkk moldova roche product limit srl chisinau mdl roche innovation center copenhagen hoersholm dkk morocco roche casablanca mad dominican republic producto roche dominicana srl santo domingo dop myanmar roche myanmar company limited yangon usd ecuador roche ecuador quito usd netherlands kapa biosystem amsterdam usd egypt roche egypt manufacturing trading sae cairo egp roche diabetes care nederland almere eur roche egypt llc cairo egp roche diagnostic nederland almere eur rodiagnostic egypt trading sae giza egp roche finance europe woerden eur salvador productos roche salvador san salvador svc roche nederland woerden eur estonia roche eesti tallinn eur roche pharmholde woerden eur finland roche diagnostic espoo eur new zealand roche diagnostic limited auckland nzd roche espoo eur roche product new zealand limited auckland nzd roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group share capital equity interest share capital equity interest country company city millions country company city millions nicaragua productos roche nicaragua managua nio united arab emirate roche diabetes care middle east fzco dubai ae nigeria roche product limited lago ngn roche diagnostic middle east fzco dubai ae norway roche diagnostic norge oslo nok roche middle east fzco dubai ae roche norge oslo nok roche pharmaceutical middle east fzco dubai ae pakistan roche pakistan limited karachi pkr united kingdom intermune bristol limited welwyn garden city gbp palestine roche pharmaceuticals palestine ltd ramallah albireh usd intermune holding limit welwyn garden city gbp panama productos roche panama panama city pab intermune limited welwyn garden city gbp producto roche interamericana prisa panama city usd intermune limited welwyn garden city gbp peru producto roche qumica farmacutica lima pen kapa biosystems ltd london gbp roche farma peru lima pen pirame limited welwyn garden city gbp philippine roche philippines inc taguig city php roche diabetes care limited burgess hill gbp poland roche diabetes care polska warsaw pln roche diagnostics ltd burgess hill gbp roche diagnostic polska warsaw pln roche hold limited welwyn garden city gbp roche polska warsaw pln roche product limit welwyn garden city gbp portugal roche farmacutica qumica lda amadora eur roche registration limited welwyn garden city gbp roche sistemas diagnsticos sociedade unipessoal lda amadora eur united states life sciences corporation little fall usd puerto rico roche products inc ponce usd adheron therapeutics inc wilmington usd syntex puerto rico inc ponce usd anadys pharmaceuticals inc south san francisco usd romania roche romania srl bucharest ron ariosa diagnostics inc san jose usd russian federation limited liability company roche diabete care rus moscow rub bina technologies inc belmont usd limited liability company roche diagnostic rus moscow rub bioveris corporation indianapoli usd roche moscow ltd moscow rub forsight vision inc south san francisco usd serbia roche doo beograd belgrade eur genentech usa inc south san francisco usd singapore roche diabete care asia pacific pte ltd singapore sgd genentech inc south san francisco usd roche diagnostic asia pacific pte ltd singapore sgd geneweave biosciences inc los gatos usd roche singapore pte ltd singapore sgd genia technologies inc santa clara usd roche singapore technical operations pte ltd singapore usd hlr consumer health inc little fall usd slovakia roche slovensko sro bratislava eur hoffmannla roche inc little fall usd slovenia roche farmacevtska druzba doo ljubljana eur igen international inc pleasanton usd south africa kapa biosystem pty ltd cape town zar intermune inc south san francisco usd roche diabete care south africa pty ltd randburg zar iquum inc marlborough usd roche product proprietary limited illovo zar kapa biosystems inc wilmington usd south korea roche diagnostics korea ltd seoul krw memory pharmaceuticals corp little fall usd roche korea company ltd seoul krw roche carolina inc florence usd spain emminens healthcare service madrid eur roche diabetes care inc indianapolis usd roche diabetes care spain barcelona eur roche diagnostic corporation indianapoli usd roche diagnostic barcelona eur roche diagnostic hematology inc westborough usd roche farma madrid eur roche diagnostic operations inc indianapoli usd sri lanka roche product colombo private limited colombo lkr roche health solutions inc indianapoli usd sweden roche stockholm sek roche holdings inc south san francisco usd roche diagnostic scandinavia bromma sek roche laboratory inc little fall usd switzerland biopharm basel chf roche molecular systems inc pleasanton usd hoffmannla roche ltd basel chf roche palo alto llc south san francisco usd hoffmannla roche ltd basel chf roche sequencing solutions inc pleasanton usd intermune international basel chf roche tcrc inc new york usd museum tinguely basel chf seragon pharmaceuticals inc south san francisco usd phaor basel chf spring bioscience corp pleasanton usd rabbitair ltd bachenblach chf tensha therapeutics inc south san francisco usd roche capital market ltd basel chf ventana medical systems inc tucson usd roche chemische unternehmungen basel chf uruguay roche international ltd montevideo branch montevideo uyu roche diabetes care switzerland ltd rotkreuz chf venezuela productos roche caracas vef roche diabetes care ltd rotkreuz chf vietnam roche vietnam ltd chi minh city usd roche diagnostic switzerland ltd rotkreuz chf share capital local currency unit roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm rotkreuz chf tavero basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie tunis tnd turkey roche diagnostic turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group significant accounting policy cost sale cost sale include correspond direct production cost relate production overhead good sell service render consolidation policy royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur subsidiary company group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary research development divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction internal research development activity expense incur follow occur control obtain result loss control associate company internal research cost incur purpose gain new scientific technical knowledge understanding group exercise power exercise significant influence control account internal development cost incur application research finding knowledge plan develop new product equity method commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market segment report postmarkete study regulatory approval phase cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require purpose segment report group corporate executive committee cec consider group chief operate regulatory authority undertaken safety commercial reason cost postmarkete study decision maker determination group operate segment base organisation unit information report capitalise intangible asset opinion management generate separately identifiable incremental future cec regular basis information provide basis segment revenue profit disclosure report economic benefit reliably measure note geographic analysis base location customer select segment balance sheet information routinely provide cec acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase capitalise intangible asset acquire asset control group separately transfer price operate segment set arm length basis operate asset liability consist property plant identifiable expect generate future economic benefit uncertainty exist research development equipment goodwill intangible asset trade receivablespayable inventory asset liability provision ultimately result marketable product consequently upfront milestone payment party pharmaceutical product reasonably attribute report operating segment nonoperate asset liability mainly include current compound regulatory marketing approval recognise intangible asset asset acquire arrangement defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable measure basis set intangible asset policy subsequent internal research development cost incur post security investment debt acquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset foreign currency translation annual financial statement present swiss franc group company use local currency functional licensing milestone upfront receipt currency certain group company use currency dollar swiss franc euro functional currency currency primary economic environment entity operate local transaction currency initially royalty income recognise accrual basis accordance substance respective licensing agreement report exchange rate date transaction gain loss settlement transaction gain collectability royalty reasonably assure royalty recognise revenue cash receive certain loss translation monetary asset liability denominate currency include income group company receive upfront milestone similar payment party relate sale licensing product qualify cash flow hedge arise monetary item substance form group net investment foreign entity technology revenue associate performance milestone recognise base achievement deliverable define case gain loss defer comprehensive income respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing consolidation asset liability group company functional currency swiss franc translate swiss obligation franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit sharing revenue bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige sale represent amount receive receivable good supply customer deduct trade discount cash discount past practice create constructive obligation volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit record accrual basis consistent recognition related sale estimate expect sale return chargeback expect cost benefit accrue period employment change carry value longterm rebate include medicaid similar rebate country deduct sale record employee benefit liability recognise operating result accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale termination benefit payable employment terminate group normal retirement date return revenue reliably measure sale recognise right return expire employee accept voluntary redundancy exchange benefit termination cost recognise early generally prescription product patient revenue record earn service perform single group long withdraw offer benefit group recognise related restructuring cost transaction split separately identifiable component reflect substance transaction necessary conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group pension postemployment benefit lease define contribution plan group contribution recognise operating result employee render group lessee finance lease exist substantially risk reward ownership transfer associate service prepay contribution recognise asset extent cash refund reduction future group finance lease capitalise start lease fair value present value minimum lease payment low payment available rental obligation net finance charge report debt finance lease asset depreciate short lease term useful life interest element lease payment charge income lease term base effective define benefit plan liability recognise balance sheet present value define benefit obligation fair interest rate method operating lease exist substantially risk reward ownership transfer group value plan asset change net define benefit liability recognise occur follow payment operating lease charge income straightline basis period lease recognise income statement group lessor certain asset mainly diagnostic instrument lease party finance current service cost charge appropriate income statement head operating result operate lease arrangement finance lease asset report receivables equal net investment lease past service cost include curtailment gain loss recognise immediately general administration operate lease income finance lease recognise term lease base effective interest rate method operating lease result asset report property plant equipment lease income operating lease recognise lease term settlement gain loss recognise general administration operating result straightline basis net interest net define benefit liability recognise financing cost recognise comprehensive income business combination actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption business combination account acquisition method accounting date acquisition group initially return plan asset exclude amount include net interest net define benefit liability recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire change limit recognition plan asset exclude amount include net interest net define benefit liability business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value net interest net define benefit liability comprise interest income plan asset interest cost define benefit acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense obligation interest effect limit recognition pension asset net interest calculate incur general administration expense discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment goodwill pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment equity compensation plan fair value equity compensation award grant employee estimate grant date record expense intangible asset vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record purchase patent licence trademark intangible asset initially record cost asset acquire change equity business combination initially record fair value available use intangible asset amortise straight line basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate property plant equipment useful live major class amortisable intangible asset follow property plant equipment initially record cost purchase construction include cost directly attributable product intangible use year bring asset location condition necessary capable operating manner intend management marketing intangible use year include item cost site preparation installation assembly cost professional fee net cost test technology intangible use year asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate impairment property plant equipment intangible asset useful live major class depreciable asset follow impairment assessment carry evidence asset impair addition intangible asset land improvement year available use test impairment annually recoverable asset high fair value building year cost disposal value use carrying value carry value reduce recoverable machinery equipment year reduction report income statement impairment loss value use calculate estimate cash flow generally diagnostic instrument year fiveyear period extrapolate projection subsequent year discount appropriate longterm office equipment year interest rate impairment loss arise useful life asset review necessary future depreciation motor vehicle year amortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse part item property plant equipment different useful life account separate component income statement impairment reversal estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group impairment goodwill financial instrument goodwill assess impairment reporting date additionally test annually impairment goodwill allocate financial instrument classify follow category disclose note cashgenerate unit recoverable cashgenerate unit high fair value cost disposal value use carrying value carry value goodwill reduce recoverable availableforsale nonderivative financial asset designate classify reduction report income statement impairment loss acquire business include cash financial asset category availableforsale asset initially record subsequently carry fair value change fair value generate unit permanently cease operate treat disposal business separately identifiable goodwill record comprehensive income impairment interest foreign exchange component investment generate initial acquisition business factor goodwill entirely unrelated derecognised cumulative gain loss equity reclassify financial income expense availableforsale asset continue operation cashgenerating unit goodwill deem dispose fully impair mainly comprise marketable security impairment testing methodology describe note fair value hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk derivative financial instrument initially record subsequently carry fair value inventory apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility fair value designate nonderivative financial instrument designate fair value profit loss initial cost determine weighted average method net realisable value estimate selling price cost completion recognition designate fair value instrument initially record subsequently carry fair value change fair value selling expense record income statement designate fair value instrument mainly comprise contingent consideration liability change fair value record general administration operating result account receivable loan receivables nonderivative financial asset fix determinable payment quote active market loan receivables initially record fair value subsequently carry amortise cost effective interest account receivable carry original invoice allowance doubtful account trade discount cash rate method impairment loss loan receivables mainly comprise account receivable cash cash discount volume rebate similar allowance allowance doubtful account record objective evidence equivalent group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense financial liability nonderivative financial liability financial liability initially record fair value doubtful trade receivables recognise marketing distribution expense trade discount cash discount volume subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt rebate similar allowance record accrual basis consistent recognition relate sale estimate trade payable base exist contractual obligation historical trend group experience financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership cash cash equivalent financial asset transfer financial liability derecognise contractual obligation discharge cancel expire cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change impairment financial asset fair value maturity month date acquisition financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty available provision contingency forsale equity security market value original cost market value original cost sustain sixmonth period consider impair provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan financial asset carry amortise cost impairment charge difference carry value recoverable commence implementation announce provision record estimate ultimate liability expect calculate estimate future cash flow discount original effective interest rate availableforsale financial arise discount time value money material contingent liability disclose existence obligation asset impairment charge currently carry comprehensive income difference original confirm future event obligation measure reasonable reliability contingent cost fair value asset recognise disclose inflow economic benefit probable impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold fair value availableforsale reversal recognise directly comprehensive income fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available roche finance report roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement roche group hedge accounting change accounting policy group use derivative manage exposure foreign currency interest rate equity market credit risk instrument group implement minor amendment exist standard interpretation material impact include interest rate swap crosscurrency swap forwards contract option group generally limit use group overall result financial position hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship future new revise standard qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group currently assess potential impact new revise standard interpretation expense mandatory january group apply base analysis date group anticipate material impact group overall result financial position cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record group assess new revise standard mandatory fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable ifrs financial instrument group plan implement new standard effective january apply exemption forecast transaction result recognition nonfinancial item cumulative change fair value hedge retrospective application classification measurement requirement include impairment mean instrument record comprehensive income include initial carrying value nonfinancial item comparative result restate new standard apply hedge accounting requirement apply date recognition cash flow hedge cumulative change fair value hedge instrument prospectively new standard result increase volume disclosure information annual financial statement record comprehensive income include financial income expense forecast transaction affect net income standard deal classification recognition measurement include impairment financial instrument gain fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm loss group currently recognise statement comprehensive income remeasure asset classify commitment identify portion asset liability firm commitment attributable particular risk affect availableforsale future recognise income statement asset classify fair value profit profit loss hedge instrument record fair value hedge item record previous carrying value adjust loss equity fair value comprehensive income irrevocable option impairment change fair value attributable hedged risk change fair value report financial income expense financial asset include trade lease receivables assess expect loss model incur loss model new standard introduce new hedge accounting model require hedge accounting relationship base group risk management strategy objective discontinue relationship long qualify hedge debt accounting group initial assessment exist hedge relationship continue designate new hedge accounting requirement debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise ifrs revenue contract customer group plan implement new standard effective january duration debt instrument recognise finance cost effective interest rate method apply retrospective method transition normally mean comparative result restate new standard apply group anticipate new standard actually change amount revenue recognise restatement necessary group plan use practical expedient taxation disclose transaction price allocate remain performance obligation new standard result increase volume disclosure information annual financial statement income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general new standard contain new set principle recognise measure revenue new requirement administration expense related presentation core principle framework revenue recognise dependent transfer promise good service customer reflect consideration receive exchange good liability income taxis mainly withhold taxis arise remittance retain earning principally relate service objective standard provide fivestep approach revenue recognition include identify contract subsidiary recognise probable earning remit foreseeable future customer identify performance obligation determine transaction price allocate transaction price performance obligation tax liability uncertain accrual record income tax liability management well estimate ultimate liability recognise revenue performance obligation satisfy expect arise base specific circumstance group historical experience ifrs lease group plan implement new standard effective january apply cumulative catchup defer tax asset liability recognise temporary difference tax basis asset liability method transition mean comparative result restate new standard apply new carry value defer tax asset recognise extent probable future taxable profit available standard result increase volume disclosure information annual financial statement unused tax loss utilise main impact new standard bring operating lease onbalance sheet group assess potential impact current defer tax asset liability offset income taxis levy taxation authority currently anticipate new standard result carry value property plant equipment increase legally enforceable right offset defer taxis determine base currently enact tax rate applicable chf billion debt increase similar application new standard result currently tax jurisdiction group operate report operating lease cost record interest expense give lease involve current low interest rate environment group currently expect effect material equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan roche finance report roche finance report roche group report roche management internal control financial report statutory auditor report roche group report roche management internal control financial report statutory auditor report general meeting roche holding ltd basel report roche management internal control financial reporting report audit consolidated financial statement board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting opinion standard audit consolidated financial statement roche holding ltd subsidiary group comprise internal control system matter design inherent limitation system determine consolidated balance sheet december consolidated income statement consolidate statement effective prevent detect misstatement provide reasonable assurance respect financial statement comprehensive income consolidate statement change equity consolidate statement cash flow year preparation presentation projection evaluation effectiveness future period subject risk control end note consolidate financial statement include summary significant accounting policy inadequate change condition degree compliance policy procedure deteriorate opinion consolidated financial statement page true fair view consolidate financial position group december consolidated financial performance consolidated cash flow year end accordance international financial reporting standard ifrs comply swiss law management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework version issue committee sponsor organization treadway commission coso base assessment management basis opinion conclude system internal control financial reporting effective december conduct audit accordance swiss law international standard auditing isa swiss audit statutory auditor kpmg audit consolidated financial statement roche holding ltd year end standard responsibility provision standard describe auditor responsibility december accordance swiss auditing standard international standard audit isa audit consolidate financial statement section report independent group accordance issue report effectiveness group system internal control financial reporting report set provision swiss law requirement swiss audit profession iesba code ethic professional accountant fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion key audit matter christoph franz alan hippe chargeback rebate sale return pharmaceuticals business chairman board director chief financial officer basel january carry value goodwill relate diagnostic division carry value productrelate intangible asset provision contingent liability respect litigation uncertain tax position key audit matter matter professional judgement significance audit consolidated financial statement current period matter address context audit consolidated financial statement form opinion thereon provide separate opinion matter roche finance report roche finance report roche group statutory auditor report statutory auditor report roche group chargeback rebate sale return pharmaceutical business carrying value goodwill relate diagnostic division key audit matter response key audit matter response group pharmaceutical business make sale audit procedure include test group goodwill chf million arise audit procedure include test customer fall certain commercial group key control relate deduction past acquisition diagnostic division principally group key control surround carry value governmentmandate contract purchase gross sale chargeback rebate sale corangeboehringer mannheim ventana goodwill relate diagnostic division reimbursement arrangement significant return include control accrual rate business sequence business area goodwill medicaid drug discount program management calculation accrue liability assess impairment reporting date audit goodwill include assess group group provide right return customer provision deduction account receivable additionally test annually impairment budgeting procedure forecast base certain product return period case integrity discount cash flow model extend year future arrangement obtain management calculation accrue impairment testing use future cash flow projection base management prepare valuation challenge result deduction gross amount invoice arrive liability provision account receivable deduction recent business plan approve management robustness key assumption determine revenue create obligation group provide recalculate amount validate assumption include estimate sale volume price business recoverable amount include identification customer chargeback rebate reference internal external source include plan project year sequence allocation cgu forecast cash flow growth rate credit sale return unsettled amount estimate term applicable contract government pricing business project year reflect long discount rate base understanding deduct gross sale record accrue liability information historical chargeback rebate period require development technology commercial prospect diagnostic business rebate provision sale return deduction historical sale return level current trend product necessary grow business market operate account receivable chargeback estimate base analyse exist contractual legislatively consider accuracy management estimate management need apply considerable judgement valuation specialist mandate obligation historical trend group previous year compare historical accrue liability allocate goodwill appropriate business assist evaluate assumption methodology experience provision account receivable deduction record assess future performance prospect management particular relate actual amount assess change cashgenerate unit cgu discount rate discount rate compare relevant assumption management determine accrue liability accrual rate estimate include apply certain business face uncertaintie technical industry economic forecast addition identify deduction account receivable expect chargeback respond increase utilisation drug commercial viability leadingedge nextgeneration analyse change assumption prior period rebate predominantly medicaid chf million discount program compare accrual rate technology product develop assessment consistency assumption necessary december additionally provision current chargeback rebate payment sale perform comparison assumption publicly sale return mainly relate product near loss return trend focus area light judgement available datum perform retrospective exclusivity chf million record estimation require history impairment record assessment accuracy management past december consider adequacy group revenue previous year amount headroom projection compare historical forecast actual recognition accounting policy include recognition cgus result focus area arrangement measurement deduction gross sale relate complex establish appropriate year chargeback rebate sale return relate forecast support carry value end position require significant judgement estimation disclosure goodwill exceed usual period year management assumption require estimating case goodwill relate sequence provision sale return complicated business challenge management reason give recent impending loss exclusivity assessment management ability group pharmaceutical product forecast cash flow long period reasonable accuracy information chargeback rebate sale return pharmaceutical business refer follow assess group disclosure sensitivity outcome impairment assessment significant accounting policy note general accounting principle key accounting judgement change key assumption reflect risk inherent estimate assumption note page financial disclosure note account receivable note valuation goodwill current liability note provision contingent liabilitie information carry value goodwill relate diagnostic division refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note goodwill roche finance report roche finance report roche group statutory auditor report statutory auditor report roche group carry value productrelate intangible asset provision contingent liability respect litigation key audit matter response key audit matter response group significant productrelate intangible asset audit procedure include test pharmaceutical industry heavily regulate discuss status significant know actual december chf million acquire group key control surround carry value increase inherent litigation risk normal course potential litigation inhouse legal counsel business combination inlicense arrangement productrelate intangible asset business provision contingent liability arise management director knowledge comprise product intangible use chf million productspecific general legal proceeding matter challenge decision rationale amortise product intangible available audit productrelate intangible asset use antitrust government investigation provision hold decision record provision use chf million amortise impairment include assess group process key control december group hold provision chf disclosure significant matter assessment carry productrelate intangible identify trigger event circumstance million respect legal action give highly complex assess relevant historical recent judgment evidence asset impaired evidence asset impair nature regulatory legal case management apply pass court authority consider legal intangible asset available use challenge robustness key assumption significant judgement consider opinion obtain management external lawyer test impairment annually determine recoverable amount include forecast provide potential exposure matter challenge basis provision record revenue profit margin useful life discount estimate change substantially time disclosure group product intangible use chf million predominantly rate challenge base understand new fact emerge legal case progress relate acquire product launch commercial prospect individual product forensic compliance specialist key risk ability successfully commercialise relevant business area market focus area give number complexity assist assessment group internal audit product concern large single intangible asset operate valuation specialist assist magnitude potential exposure group report compliance log report prepare arose acquisition intermune relate evaluate assumption methodology judgement necessary determine management identify actual potential noncompliance esbriet chf million focused area give management particular relate discount amount provide andor disclose law regulation specific group assess recoverability product intangible use rate assessment relation key business relate conduct business base forecasting discount future cash flow input project pricing volume product generally inherently highly judgemental key estimate project share therapeutic area vitro diagnostic assumption include revenue growth loss exclusivity market profit margin compare relevant assumption matter management conclude profit margin discount rate development industry forecast review analyst commentary provision record consider commercialisation compete product retrospective assessment accuracy previous adequacy completeness group disclosure projection consider high risk relation contingent liability product intangible available use chf million impairment perform sensitivity analysis individual represent inprocess research development intangible asset impairment model assess level information provision contingent liability respect litigation refer follow asset inherent uncertainty research sensitivity key assumption focus work development process intangible asset available area significant accounting policy note general accounting principle key accounting judgement use particularly risk impairment impairment estimate assumption note financial disclosure note provision contingent liability assessment require management key assumption productrelate intangible available judgement clinical technical commercial use audit addition procedure include viability new product accordingly focus assess reasonableness management assumption audit work area risk include inability probability obtain regulatory approval achieve successful trial result obtain require clinical comparison industry practice past history regulatory approval highly competitive business consideration group internal governance environment therapeutic area group approval process interview number senior significant asset research development research development commercial personnel order understand challenge assumption information carry value productrelate intangible asset refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note intangible asset roche finance report roche finance report roche group statutory auditor report statutory auditor report roche group information annual report uncertain tax position board director responsible information annual report information comprise information include annual report include consolidated financial statement standalone financial statement company remuneration report auditor report thereon key audit matter response group operate wide range different challenge management judgement opinion consolidate financial statement cover information annual report tax jurisdiction world subject eventual resolution national tax authority double express form assurance conclusion thereon occasional challenge local tax authority include taxation conflict pende tax audits estimate tax crossborder transfer pricing arrangement good exposure assistance local country tax connection audit consolidated financial statement responsibility read information service finance transactionrelate tax matter specialist significant uncertain tax position annual report consider information materially inconsistent consolidated financial connection integration investment divestment work include assessment thirdparty opinion statement knowledge obtain audit appears materially misstate base work licensing contract area particular focus include use available past experience perform conclude material misstatement information require report fact transfer pricing arrangement relate tax authority respective jurisdiction additionally report regard group manufacture supply chain tax specialist expertise assess appropriateness key assumption tax liability uncertain group management conclude good estimate responsibility board director consolidate financial statement recognise accrual reflect management good estimate outcome outcome base fact know relevant board director responsible preparation consolidate financial statement true fair view jurisdiction group open tax transfer pricing audit approach include additional audit procedure accordance ifrs provision swiss law internal control board director determine matter tax authority range perform group level consider significant necessary enable preparation consolidated financial statement free material misstatement possible outcome broad december uncertain tax position particular transfer price apply fraud error group recognise current income tax liability good service intellectual property right chf million include accrual uncertain prepare consolidated financial statement board director responsible assess group ability tax position continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate group cease operation realistic focused area estimate amount alternative tax receivable payable require significant level expertise judgement auditor responsibilitie audit consolidated financial statement information uncertain tax position refer follow objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error issue auditor report include opinion significant accounting policy note general accounting principle key accounting judgement reasonable assurance high level assurance guarantee audit conduct accordance swiss estimate assumption note page financial disclosure note income taxis law isa swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement audit accordance swiss law isa swiss auditing standard exercise professional judgment maintain professional scepticism audit identify assess risk material misstatement consolidated financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure conclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease continue go concern roche finance report roche finance report roche group statutory auditor report report independent auditor internal control financial reporting roche group report independent auditor evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement represent underlie transaction event manner achieve fair presentation internal control financial reporting obtain sufficient appropriate audit evidence financial information entity business activity group express opinion consolidated financial statement responsible direction supervision performance group audit remain solely responsible audit opinion board director roche holding ltd basel communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit examine roche group system internal control financial reporting december base criterion establish internal control integrate framework version issue committee sponsor provide board director relevant committee statement comply relevant ethical organization treadway commission coso requirement independence communicate relationship matter reasonably think bear independence applicable related safeguard board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include matter communicate board director relevant committee determine matter accompany report roche management internal control financial reporting responsibility express significance audit consolidated financial statement current period key opinion group internal control financial reporting base examination entity internal control audit matter describe matter auditor report law regulation preclude public disclosure financial reporting process effect entitys board director management personnel design matter extremely rare circumstance determine matter communicate report provide reasonable assurance reliability financial statement prepare accordance international adverse consequence reasonably expect outweigh public interest benefit financial reporting standard ifrs include policy procedure pertain maintenance communication record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention report legal regulatory requirement timely detection unauthorised acquisition use disposition entitys asset material effect entity financial statement accordance article para item swiss auditing standard confirm internal control conduct examination accordance international standard assurance engagement isae system exist design preparation consolidated financial statement accord instruction standard require plan perform examination obtain reasonable assurance effective board director internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness recommend consolidated financial statement submit approve internal control perform procedure consider necessary circumstance believe evidence obtain examination provide reasonable basis opinion kpmg inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree compliance policy procedure deteriorate opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework version issue ian starkey marc ziegler committee sponsor organization treadway commission coso license audit expert license audit expert auditor charge audit accordance swiss auditing standard international standard audit isa consolidated financial statement roche holding ltd year end december report date basel january january express unqualified opinion consolidated financial statement kpmg ian starkey marc ziegler license audit expert license audit expert auditor charge basel january kpmg viaduktstrasse box basel kpmg viaduktstrasse box basel kpmg subsidiary kpmg holding member kpmg network independent firm affiliate kpmg international cooperative kpmg international kpmg subsidiary kpmg holding member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve swiss legal entity right reserve roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group alternative performance measure sale division millions chf pharmaceutical diagnostic financial information include financial review include certain alternative performance measure apm total accounting measure define ifrs particular core result net work capital net operating asset free cash flow constant exchange rate apm instead consider alternative group consolidated financial result base ifrs apm comparable similarly title measure disclose company apms sale geographical area millions chf present financial review relate performance current year comparative period switzerland core result germany rest europe core result allow assessment group actual result define ifrs underlying performance europe business core result concept internal management business base ifrs result follow adjustment united states global restructuring plan note exclude rest north america amortisation impairment intangible asset note impairment goodwill note exclude north america acquisition accounting impact accounting alliance arrangement business combination financial review exclude latin america discontinue operation currently exclude legal environmental case financial review exclude japan global issue outside healthcare sector group control currently exclude rest asia material treasury item major debt restructuring note exclude asia pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price africa australia oceania underlying equity replace normalise tax benefit ifrs expense multiply applicable tax rate note total core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm addition property plant equipment division million chf group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial review pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group core result reconciliation millions chf divisional core result reconciliation million chf alliance normali alliance global intangible business legal major debt pension sation global intangible business legal pension restruc amorti intangible combi environ restruc plan ecp tax restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental ture settlement benefit core ifrs ture sation impairment nation mental settlement core sale pharmaceutical royalty operate sale income royalty operating income cost sale cost sale marketing distribution marketing distribution research development research development general administration general administration operating profit operating profit financing cost diagnostic financial income sale expense royalty operate income profit taxis cost sale marketing distribution income taxis research development net income general administration operating profit attributable roche shareholder corporate noncontrolle interest general administration operating profit core result reconciliation millions chf divisional core result reconciliation million chf alliance normali global intangible business legal major debt pension sation alliance restruc amorti intangible combi environ restruc plan ecp tax global intangible business legal pension ifrs ture sation impairment nation mental ture settlement benefit core restruc amorti intangible combi environ plan sale ifrs ture sation impairment nation mental settlement core royalty operating pharmaceutical income sale cost sale royalty operate income marketing distribution cost sale research development marketing distribution general administration research development operating profit general administration operating profit financing cost financial income diagnostic expense sale profit taxis royalty operating income cost sale income taxis market distribution net income research development general administration attributable operating profit roche shareholder noncontrolle interest corporate general administration operating profit roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group core ep basic operate free cash flow free cash flow calculate show table additional commentary adjustment item give financial review core net income attributable roche shareholder chf million operate free cash flow reconciliation million chf weight average number share nonvoting equity security issue million core earning share basic chf cash flow operating activity ifrs basis accordance ia add income taxis pay deduct core eps dilute investment property plant equipment investment intangible asset disposal property plant equipment core net income attributable roche shareholder chf million disposal intangible asset increase noncontrolle interest share core net income assume outstanding chugai stock pension postemployment benefit option exercise chf million add total payment define benefit plan net income calculate diluted earning share chf million deduct allocation payment operate free cash flow operating item weight average number share nonvoting equity security issue operate free cash flow calculate dilute earning share million core earning share diluted chf free cash flow reconciliation million chf free cash flow cash flow operating activity ifrs basis accordance ia deduct free cash flow assess group ability generate cash require conduct maintain operation indicate investment property plant equipment group ability generate cash finance dividend payment repay debt undertake merger acquisition activity investment intangible asset free cash flow concept internal management business disposal property plant equipment disposal intangible asset operate free cash flow calculate base ifrs operating profit adjust certain cash item movement net working interest pay capital capital expenditure investment property plant equipment intangible asset operate free cash flow different operating item cash flow operating activity define ias include capital expenditure responsibility treasury item divisional management exclude income taxis pay responsibility divisional management cash outflow free cash flow define benefit plan allocate operate free cash flow base current service cost residual allocate treasury activity free cash flow calculate operate free cash flow adjust treasury activity taxis pay free cash flow different total cash flow define ia exclude dividend payment cash inflowsoutflow financing activity issuancerepayment debt purchasesale marketable security cash inflowsoutflow merger acquisition divestment group refine calculation free cash flow exclude dividend line peer group free cash flow restate accordingly result increase chf million free cash flow period impact operate free cash flow change roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group supplementary information calculate divisional operate free cash flow show table net operating asset divisional operate free cash flow information million chf net operating asset allow assessment group operate performance business independently finance tax activity net operating asset calculate property plant equipment goodwill intangible asset net work capital pharmaceutical diagnostic corporate group longterm net operating asset minus provision depreciation amortisation impairment depreciation property plant equipment calculation net operating asset disclose note annual financial statement show table amortisation intangible asset impairment property plant equipment net operating asset reconciliation millions chf impairment goodwill taxation impairment intangible asset pharmaceutical diagnostic corporate treasury roche group total property plant equipment goodwill adjustment intangible asset add inventory expense equitysettle equity compensation provision plan current income tax net liability net income expense provision defer tax net asset net gain loss disposal define benefit plan net liability noncash work capital item marketable security deduct cash cash equivalent utilisation provision debt proceed disposal net asset liability total net work capital longterm net operating asset operate profit cash adjustment total net operating asset ebitda net operating asset reconciliation millions chf group use earning interest tax depreciation amortisation ebitda internal management taxation report external communication opinion group management operate free cash flow give useful pharmaceutical diagnostic corporate treasury roche group consistent measurement cash earning ebitda include noncash item provision allowance trade property plant equipment receivables inventory certain noncash entry arise acquisition accounting pension accounting goodwill intangible asset convenience reader use ebitda provide table start point use core inventory result exclude amortisation impairment goodwill intangible asset provision current income tax net liability ebitda core result millions chf defer tax net asset define benefit plan net liability pharmaceutical diagnostic corporate group marketable security ebitda cash cash equivalent core operate profit debt depreciation impairment property plant net asset liability equipment core basis net work capital ebitda longterm net operating asset margin sale total net operating asset roche finance report roche finance report roche group multiyear overview supplementary information roche security roche group roche security net debt net debt monitor group overall short longterm liquidity net debt calculate sum total debt longterm shortterm marketable security cash cash equivalent net debt calculation include detail movement current year show table financial review price development share chf net working capital net working capital assess group efficiency utilise asset shortterm liquidity net trade working capital iscalculate trade receivables inventory minus trade payable net work capital calculate net trade work capital adjust receivables payable net work capital net trade work capital calculation show table pharmaceutical division diagnostic division corporate financial review roche share swiss market index rebase constant exchange rate certain percentage change financial review calculate constant exchange rate cer allow assessment group financial performance effect exchange rate fluctuation eliminate percentage change price development nonvoting equity security genussschein chf constant exchange rate calculate simulation reconsolidate current report period prior period number constant currency exchange rate equal average exchange rate prior year example cer change line item equivalent calculate average exchange rate year end december line item line item subsequently calculate change percent respect recalculate number foreign exchange gain loss exclude calculation cer growth rate earn share calculation country significant devaluation local currency current year simulation use average exchange rate current year instead prior year avoid cer growth rate artificially inflate roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july information table restate change ratio adr effective january change ratio adr effective january change ratio adr effective february roche finance report roche finance report roche group roche security roche holding ltd basel number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value financial statement total number share nonvoting equity security note financial statement genussscheine hold total issue summary significant accounting policy ignificant shareholder hareholders equity ulltime equivalent contingent liability board executive shareholding datum share nonvoting equity security chf appropriation available earning earning basic statutory auditor report general meeting roche holding ltd basel earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend stock price share open high low yearend stock price nonvoting equity security genussschein open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange rog bloomberg rog rhhby reuters ros rogvx rhhbypk roche finance report roche finance report roche holding ltd basel financial statement financial statement roche holding ltd basel financial statement income statement millions chf year end december income income investment dividend income balance sheet million chf financial income interest income loan group company december december income marketable security current asset guarantee fee income group company cash cash equivalent income marketable security total income account receivable group company shortterm loan group company expense current receivables administration expense total current asset expense financial expense noncurrent asset direct taxis longterm loan group company total expense investment total noncurrent asset net income total asset shortterm liability account payable group company shortterm liability total shortterm liability longterm liability provision total longterm liability total liability shareholders equity share capital nonvoting equity security genussscheine legal retain earning general legal retain earning voluntary reserve retain earning free reserve special reserve available earning balance bring forward previous year net income year equity instrument total shareholder equity total shareholder equity liability pro memoria nonvoting equity security nominal value roche finance report roche finance report roche holding ltd basel note financial statement note financial statement roche holding ltd basel note financial statement equity instrument company purchase roche share company sell roche share roche share average sale price chf share chf share net gain chf million net gain chf million dividend income amount chf million chf million summary significant accounting policy december company hold roche share december company hold roche share cost chf million deduct equity number equity instrument hold company subsidiary basis preparation exclude foundation meet definition requirement article roche group annual financial statement entity mainly foundation include consolidation qualify subsidiary article financial statement roche holding ltd basel company prepare accordance provision swiss law accounting financial report title swiss code obligation prescribe law significant movement recognise amount million chf accounting principle apply describe legal voluntary reserve retain earning share retain free special available equity total company prepare consolidated financial statement accordance recognise accounting standard international capital earning reserve reserve earning instrument equity financial reporting standard accordance company decide forgo present additional information audit fee january note cash flow statement net income dividend transaction equity instrument valuation method translation foreign currency december marketable security report low cost market value financial asset include investment report net income cost appropriate writedown equity instrument recognise cost deduct equity time purchase dividend equity instrument sell gain loss recognise income statement asset liability denominate transaction equity instrument foreign currency translate swiss franc yearend rate exchange investment translate december historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception net income unrealise gain defer dividend transaction equity instrument december investment major direct indirect investment company list note roche group annual financial statement ownership interest equal voting right contingent liability taxis guarantee direct taxis include corporate income capital taxis company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december chf billion chf billion describe note roche group annual financial statement shareholder equity significant shareholder share capital previous year share capital amount chf million share capital consist bearer share nominal value chf include equity nonvoting equity security genussscheine share share company bearer share reason company register shareholder follow capital confer voting right nonvoting equity security confer right share participate figure base information shareholder shareholder validation check annual general meeting march available earning remain proceed liquidation follow repayment nominal value share capital information available company participation certificate roche finance report roche finance report roche holding ltd basel note financial statement note financial statement roche holding ltd basel control shareholder corporate executive committee december base information supply group shareholder group pool voting right own member corporate executive committee person closely associate hold share nonvoting equity security share represent issue share group consist vera michalskihoffmann maja show table hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure shareholding member corporate executive committee include share pooled voting right hold outside group individual member group maja oeri nonvoting equity security member pool hold share represent voting right independently pool share genussscheine december base information supply group share share own novartis schwan holding basel participation ayyoubi diggelmann hippe keller oday fulltime equivalent wilbur total equity compensation award ssar rsus roche performance share plan annual average number fulltime equivalent exceed people close relative keller hold roche share roche share december members corporate executive committee hold stocksettle stock appreciation right ssar show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page board executive shareholding ssar award hold december board director year issue total schwan director andr hoffmann andreas oeri certain member founder family closely associate diggelmann belong shareholder group pool voting right end group hold share hippe issue share detailed information group give note addition end year member board keller director person closely associate hold share nonvoting equity security genussscheine show oday table wilbur total cec annual general meeting march prof pius baschera stand reelection mrs anita hauser nominate election new member board director strike price chf expiry date mar mar mar mar mar feb feb shareholdings members board director december members corporate executive committee hold restrict stock unit rsus show table nonvoting equity security term vest condition award disclose note roche group annual financial statement share genussscheine additional supplementary information remuneration report include annual report page rsus franz remuneration component corporate executive committee replace award correspond performance share plan hoffmann psp award rsu award vest recipient year nonvoting equity security remain baschera block year bell brown rsu award hold december bulcke julius year issue total lifton schwan oeri diggelmann poussot hippe schwan keller sssmuth dyckerhoff oday voser wilbur weder mauro total cec total include share hold shareholder group pool voting right member corporate executive committee schwans shareholdings disclose table jointly hold close relative roche finance report roche finance report roche holding ltd basel note financial statement appropriation available earning roche holding ltd basel appropriation available earning december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page award result zero nonvoting equity security share value adjustment depend achievement performance target discretion board director vest nonvoting equity security share remain block year end cycle performance target achieve accordingly participant receive originally target nonvoting equity security total target number award outstanding performance cycle december show table roche performance share plan award hold december proposal annual general meeting chf psp psp schwan available earning diggelmann balance bring forward previous year hippe net profit year keller total available earning oday wilbur appropriation available earning total cec distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year allocation date feb feb total appropriation available earning information relate number value right option award grant employee roche group member carry forward account board director corporate executive committee company disclose note note roche group annual financial statement roche finance report roche finance report roche holding ltd basel statutory auditor report statutory auditor report roche holding ltd basel statutory auditor report audit accordance swiss law swiss auditing standard exercise professional judgment maintain professional scepticism audit identify assess risk material misstatement financial statement fraud error design general meeting roche holding ltd basel perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override report audit financial statement internal control obtain understand internal control relevant audit order design audit procedure appropriate opinion circumstance purpose express opinion effectiveness internal control audit financial statement roche holding ltd comprise balance sheet december evaluate appropriateness accounting policy reasonableness accounting estimate related income statement year end note financial statement include summary significant disclosure accounting policy conclude appropriateness board director use go concern basis accounting base opinion financial statement page year end december comply swiss law audit evidence obtain material uncertainty exist relate event condition cast significant company article incorporation doubt entitys ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date basis opinion auditor report future event condition cause entity cease continue go concern conduct audit accordance swiss law swiss auditing standard responsibility communicate board director relevant committee matter plan scope provision standard describe auditor responsibility audit financial statement time audit significant audit finding include significant deficiency internal control identify section report independent entity accordance provision swiss law requirement audit swiss audit profession fulfil ethical responsibility accordance requirement provide board director relevant committee statement comply relevant ethical believe audit evidence obtain sufficient appropriate provide basis opinion requirement independence communicate relationship matter reasonably think bear independence applicable related safeguard report key audit matter base circular federal audit oversight authority matter communicate board director relevant committee determine matter significance audit financial statement current period key audit matter determined key audit matter communicate report describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication responsibility board director financial statement board director responsible preparation financial statement accordance provision report legal regulatory requirement swiss law company article incorporation internal control board director determine necessary enable preparation financial statement free material misstatement fraud accordance article para item swiss auditing standard confirm internal control error system exist design preparation financial statement accord instruction board director prepare financial statement board director responsible assess entitys ability continue go concern disclose applicable matter relate going concern go concern basis accounting confirm propose appropriation available earning complie swiss law company article board director intend liquidate entity cease operation realistic alternative incorporation recommend financial statement submit approve kpmg auditor responsibility audit financial statement objective obtain reasonable assurance financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision ian starkey marc ziegler user take basis financial statement license audit expert license audit expert auditor charge basel january kpmg viaduktstrasse box basel kpmg subsidiary kpmg holding member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche finance report roche finance report publish cautionary statement forwardlooke statement hoffmannla roche ltd annual report contain certain forwardlooking statement group communication forwardlooke statement identify word basel switzerland believe expect anticipate project intend tel seek estimate future similar expression wwwrochecom discussion thing strategy goal plan intention factor cause actual result differ orderdownload publication materially future reflect forwardlooke internet rochecompublication statement contain annual report email baselwarehouseservicesrochecom pricing product initiative competitor legislative fax regulatory development economic condition delay inability obtain regulatory approval bring product medium relation market fluctuation currency exchange rate general tel financial market condition uncertaintie discovery email rochemediarelationsrochecom development marketing new product new use exist product include limitation negative result clinical investor relation trial research project unexpected effect pipeline tel market product increase government pricing pressure email investorrelationsrochecom interruption production loss inability obtain adequate protection intellectual property right litigation corporate sustainability committee loss key executive employee adverse tel publicity news coverage email corporatesustainabilityrochecom statement earning share growth profit annual general meeting forecast interpret mean roche march earning earning share subsequent period necessarily match exceed historical publish earning earning share roche trademark legally protect link thirdparty page provide convenience express opinion content thirdparty page expressly disclaim liability thirdparty information use roche finance report publish german english case doubt difference interpretation english version shall prevail german text reporting consist actual annual report finance report contain annual financial statement consolidated financial statement regard content management report article incorporation consist aforementioned report exception remuneration report print nonchlorine bleach fsccertifie paperf hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche finance report finance report